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GENERAL INTRODUCTION 
Dissertation Organization 
This dissertation is presented in the alternate format. It begins with a General 
Introduction that is followed by a Literature Review on topics related to the dissertation 
research. Then, two manuscripts that have been prepared from the data collected from the 
research project are included. These manuscripts were prepared for publication, and each one 
is complete in itself and has an abstract, introduction, materials and methods, results, 
discussion, conclusions, references, and acknowledgments. References are listed separately 
following each chapter of the dissertation. Finally, this dissertation is concluded with a 
General Summary, Appendix, and Acknowledgments. 
Background and Objectives 
The central aim of regulation of carbohydrate metabolism is to maintain glucose 
homeostasis, which results from the balance of glucose production and utilization. Both 
glucose production and glucose utilization are regulated elaborately by various mechanisms. 
For example, the liver, through regulation of hepatic glucose production and utilization (the 
latter mainly occurs in nonruminants), plays a pivotal role in maintaining glucose 
homeostasis. The liver is the major organ that performs gluconeogenesis. The flux of 
gluconeogenic substrates is controlled by both dietary and hormonal factors that mainly 
regulate key rate-controlling enzymes in the pathways of both gluconeogenesis and 
glycolysis. Phosphoenolpynivate carboxykinase (PEPCK) is one of those key regulatoiy 
enzymes. It has no known allosteric effectors and is regulated at the gene expression level, 
i.e., by transcription rates and stability of its mRNA. An abnormality in any regulators-
mechanism may result in a disturbance of glucose homeostasis such as occurs in diabetes 
mellitus. 
Because of the fermentative nature of the environment in the rumen, carbohydrate 
metabolism in ruminants differs fi-om that of nonruminants in several aspects. Dietary 
carbohydrates are fermented to volatile fatty acids in the rumen rather than being digested 
and absorbed as glucose in the small intestine. As a result, the ruminants depend on 
continuous gluconeogenesis to provide glucose, which differs greatly from nonruminants. 
Also, because glucose is required for synthesis of milk lactose during the whole lactation 
period in lactating cows, the demands for glucose are great. Thus, gluconeogenesis in 
lactating cows is very important for maintaining both glucose homeostasis and milk 
production. Because glucose metabolism differs between ruminants and nonruminants. their 
regulatory mechanisms may also differ, but the mechanistic nature of the differences has not 
been clearly elucidated. 
Lactation ketosis is a common metabolic disorder in dairy cows, and it occurs in the 
first several weeks after calving. Ketosis is associated with disturbances of both 
carbohydrate and lipid metabolism, and it is characterized by hypoglycemia, depletion of 
liver glycogen, hyperketonemia. and fatty liver. Ketosis generally is thought to result from 
endogenous glucose deficiency or low carbohydrate status. Early lactation cows are in a state 
of negative-energy balance, which indirectly causes increased lipolysis from adipose tissue. 
As a result, ketogenesis increases when the carbohydrate status is low. The specific 
biochemical aberrations causing the pathogenesis of ketosis and fatty liver, however, are still 
unidentified. For example, it is still unclear whether gluconeogenic capacity is impaired in 
cows with ketosis and fatty liver. Also, the regulation of feed intake in early lactation cows 
is poorly imderstood, and the importance of decreases in feed intake in development of 
ketosis is unclear. 
Glucagon, a polypeptide hormone containing 29 amino acids, is secreted by the 
pancreatic a-cells. Glucagon acts to regulate metabolism through specific signal 
transduction pathways that alter intracellular levels of cAMP and Ca~. Glucagon is 
considered to be a catabolic hormone that regulates carbohydrate, lipid, and protein 
metabolism, but some aspects of its regulation in vivo are still uncertain, i.e.. the lipolytic and 
proteolytic effects. The liver is the major target organ of glucagon, and one vital 
physiological role of glucagon is the maintenance of glucose homeostasis by increasing 
hepatic glucose production. Our general hypothesis for this dissertation research is that 
exogenous glucagon infused into dairy cows would increased the availability of endogenous 
glucose without also increasing the net availability of endogenous NEFA mobilized from 
adipose tissue and that hormonal regulation of gene expression for gluconeogenic enzymes is 
critical in controlling glucose homeostasis in response to hormonal status, as well as in 
development of ketosis in dairy cows. 
The present studies were undertaken mainly to gain further understanding of the 
regulation of carbohydrate metabolism by exogenous glucagon in lactating cows. Specific 
objectives were; 
1. To determine pharmacological effects of long-term intravenous infusions of 
glucagon in normal, early-lactating dairy cows with an emphasis on regulation of 
glucose metabolism. 
2. To examine changes of mRNA for selected gluconeogenic enzymes, along with 
other metabolic parameters, caused by glucagon infusion into normal lactating 
dairy cows for both long-term and short-term periods. 
3. To measure PEPCK mRNA and its response to glucagon infusion in cows that had 
fatty liver and were susceptible to ketosis. 
REVIEW OF LITERATURE 
This review of literature consists of five parts: 1) etiology of lactational ketosis. 2) 
fatty liver and its relationship with ketosis, 3) gluconeogenesis in ruminants. 4) regulation of 
gene expression of PEPCK, and 5) glucagon in ruminants. These are broad areas of 
discussion, and my intention is to provide an overview about the nature of ketosis. fatt>- liver, 
gluconeogenesis. and glucagon in dairy cows. Also, the regulation of PEPCK is reviewed at 
the molecular level. 
Etiology of Lactational Ketosis 
Definition of ketosis 
In dairy cows, ketosis is a major metabolic disorder, which generally is thought to be 
caused by disturbances of carbohydrate and lipid metabolism. Ketosis is characterized by 
hyperketonemia and hypoglycemia. Depending on the degree of clinical signs, there are two 
forms of ketosis. clinical and subclinical. Signs of ketosis include loss of appetite, decreased 
milk production, and rapid loss of body weight. Some cows become excitable; however, the 
majority is apathetic. The general biochemical changes of spontaneous ketosis are increases 
in plasma ketone bodies, NEFA, and acetate (8); decreases in plasma glucose, triglycerides. 
Cholesterol, and phospholipid (129, 215); fatty infiltration of the liver (173): loss of liver 
glycogen (149); increased milk fat content, and decreased milk protein content (184). 
Subclinical ketosis may be defined as a preclinical stage of ketosis. which is characterized by 
elevated levels of ketone bodies without clinical symptoms. Total plasma ketone bodies in 
normal cows were less than lOmg/dl (174), but the lower and upper limits of ketone bodN 
concentrations used to specify subclinical ketosis are not consistent among investigators. 
Both plasma acetoacetate and BHBA have been used as indicators of subclinical ketosis. 
Some researchers have measured only milk acetone. Subclinical ketosis is can be costly 
because the incidence can be high, and it may remain undetected; yet, it has adverse effects 
on productivity. Ketotic cows may recover spontaneously without treatment when milk 
production decreases rapidly. 
Incidence and risk factors 
Because it is not easy to differentiate between subclinically and clinically ketotic 
cows in field studies, most investigators have reported the prevalence of hyperketonemia. 
which includes both subclinical and clinical cases. The occurrence of at least one episode of 
hyperketonemia in cows during the first two months of lactation ranged from 7 to 32 percent 
(2, 54, 55 72, 77, 82, 84, 105). The incidence is significantly different between herds (3, 54. 
87), which may be related to management, nutrition, or other factors such as week of 
lactation, breed, parity, season, and milk production. Ten years ago, the peak prevalence 
usually appeared during the fourth week of lactation; however, recent studies and experiences 
of veterinarians indicate that the peak time seems to have moved to the first week of 
lactation. For instance, Duffield et al. (55) reported a survey of 1,373 dairy cows in the 
Ontario area. They defined subclinical ketosis as a serum BHBA concentration of 1.2 mM or 
higher, and the prevalence of hyperketonemia in early lactation cows was about 14%, which 
had changed very little over the previous 10 years (54). The prevalence peak, however, has 
moved from the fourth week of lactation to the first two weeks. 
Ketosis usually occurs in high-producing cows. Concentrations of ketone bodies are 
positively associated with milk yield around the peak of lactation (3, 89. 105) and with milk 
yield during the entire lactation (57). Obesity or overfeeding cows with grain during the drv-
period increased the risk to have ketosis and other peripartal diseases (68. 128, 165. 188). In 
Scandinavian countries, high butyric acid content in silage was found to be an imponant 
factor leading to occurrence of ketosis (3, 199). Butyrate is absorbed through the rumen wall 
and converted to BHBA in the rumen epithelium. 
Epidemiological studies have shown a close relationship between ketosis and other 
periparturient diseases. Among 61,124 Finnish Ayrhire cows, Grohn et al. (80) reported 15 
different disorders that increased the odds for diagnosis of ketosis. The disorders included 
parturient paresis, abomasal displacement, hypomagnesemia, retained placenta, metritis, 
mastitis, foot or leg problems, rumen acidosis, and traumatic reticuloperitonitis. Markufeld 
et al. (126), reported no association between ketonuria and either milk fever or mastitis, 
however, significant associations were established between ketonuria and retained placenta, 
primary metritis, displaced abomasum, and aciduria after calving. It is thought that the 
periparturient diseases associated with ketosis cause loss of appetite of cows and induce 
ketosis; therefore, this type of ketosis is classified as secondary ketosis. The relationship 
between ketosis and abomasal displacement may be bidirectional rather than unidirectional 
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Pathogenesis 
While the physical characteristics of lactation ketosis in cows have been well 
established, the etiology of ketosis is still not clearly elucidated. It was well known that 
under fed conditions, correlations between NEFA and glucose or ketones are low (160). 
However, under fasting conditions or in cows in the early stages of ketosis. there is a 
significant negative correlation on a within-cow basis between glucose and NEFA (-0.66) 
and glucose and ketone bodies (-0.68). with a significant positive correlation between NEFA 
and ketone bodies (0.85) (159). It is clear that NEFA are an important source of blood 
ketones, with conversion occurring in the liver under either fasting or ketotic conditions. The 
negative correlation between blood glucose and both NEFA and ketones suggests that low 
availability of glucose is an important factor in the development of ketosis. 
During early lactation, the metabolic priority given to the demands of milk production 
at a time when feed intake is limited was proposed to be a key factor in rendering dairy cows 
susceptible to spontaneous ketosis (9). Feed intake during this period is frequently 
insufficient to meet the combined metabolic demands of maintenance and milk production, 
so that cows are in negative energy balance. The metabolic priority for demands of milk 
production is probably established by changes in patterns of hormone secretion during the 
periparturient period. Lipolytic hormones promote lipid mobilization from adipose tissue for 
energy supply; thus, concentrations of plasma NEFA increase. Usually, NEFA began to 
increase two weeks before calving and peak by calving (81). However, hyperketonemia and 
hypoglycemia usually occurred in one to three weeks after calving (185, 189). The time 
course of changes in these metabolites may provide insights about the occurrence of ketosis. 
9 
Elevated plasma NEFA provide substrates for ketogenesis. but probably severe carbohydrate 
insufficiency is the precipitating factor for clinical ketosis (9). 
A glucose deficiency could result fi-om an imbalance between glucose demand for 
lactation and hepatic glucose production from gluconeogenesis. Deficiencies in glucose 
supply could be caused by inadequacies in availability of gluconeogenic precursors or by 
impairment of the gluconeogenic process. Although in vitro results from experimental 
ketosis showed impaired gluconeogenesis in the liver of ketotic cows (134). there is no in 
vivo study that directly measure gluconeogenesis of ketotic cows. Propionate loading tests 
show decreased conversion of propionate to glucose in spontaneously ketotic dairy cows 
(79); however, the propionate loading test is not a measure of in vivo gluconeogenesis in the 
liver. In addition. Smith (193) found that propionate loading was not affected by liver fat 
concentration. Studies on the activities of some key gluconeogenic enzymes are not 
conclusive, and the results are inconsistent, which will be discussed in detail in another 
section. The relatively low supply of gluconeogenic precursors compared with high demands 
for glucose for milk production might be a very important factor in initiating ketosis in early 
lactation cows, but very few studies have been conducted to approach this in depth. 
In 1966, Krebs (108) proposed that oxaloacetate (OAA) deficiency is the underlying 
cause of ketosis. When the demand for glucose is great, OAA in the tricarboxylic acid (TCA) 
cycle is removed from the mitochondria for gluconeogenesis. If OAA concentration in the 
mitochondria becomes sufficiently depleted, there will not be enough OAA to condense with 
acetyl-CoA to allow initiation of the TCA cycle. When this happens, acetyl-CoA 
accumulates in the mitochondria and is removed via production of ketone bodies. Thus. 
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gluconeogenesis, by virtue of its utilization of OAA. promotes ketoneogenesis. 
Concentrations of OAA and many other gluconeogenic intermediates decline in ketotic livers 
(13), but the intramitochondrial concentration of OAA has not yet been determined. 
Components of the TCA cycle may be depleted by excessive gluconeogenesis. by a limited 
supply of precursors, or by a more reduced redox potential. A study by Wieland et al. (209) 
showed that an increased mitochondrial redox potential influenced the OAArmalate couple in 
favor of malate. In addition. Ballard et ai. (16) showed that NADP-malate dehydrogenase 
activity was decreased in mitochondria, but activity of the enzyme within cytosol was 
increased during spontaneous ketosis. Thus, malate leaving mitochondria would supply 
precursors for gluconeogenesis. which deplete TCA cycle intermediates in mitochondria. 
Ketogenesis in ruminants could be regulated in some key steps as in nonruminants. 
Ketogenesis may be regulated by transport of NEFA from plasma to the liver. Uptake of 
NEFA by the liver is regulated by both their concentrations and by rates of blood flow (61). 
The entry rate is determined also by concentrations of malonyl-CoA, which inhibits carnitine 
palmitoyl transferase I. This mechanism is very important for control of ketogenesis in 
nonruminants (130). Malonyl-CoA also inhibits carnitine acyltransferase in both bovine and 
sheep liver (30). Zammit et al. (218) pointed out that the decreased hepatic concentration of 
malonyl-CoA. which is probably caused by hypoinsulinemia and hyperglucagonemia in late 
gestation and early lactation, stimulated oxidation of fatty acids to ketone bodies. The role of 
malony-CoA in the development of ketosis needs fiirther research because lipogenesis in the 
ruminant liver is low or absent. Also, recent evidence in nonruminants suggests that 6-
hydroxy-B-methyglutaryl-CoA synthase is an important control point for ketogenesis. and 
II 
possibly for P-oxidation. because of its highly regulated nature (136). In ruminants, 
propionate is an anti-ketogenic. Propionate inhibits oxidation of fatty acids by forming a 
nonfimctional adduct between flavin adenine dinucleotide and fatty acyl-CoA dehydrogenase 
(187). Succinyl-CoA generated from propionate in the mitochondria also inhibits 
ketogenesis by succinylating B-hydroxy-B-methyglutaryl-CoA synthase (119). 
Fatty Liver and Its Relationship with Ketosis 
Characteristics of fatty liver 
Fatty liver in dairy cows may be defined as a periparturient metabolic disorder 
characterized by fatty infiltration of the liver. Jasper (99) observed the livers of 2.400 cows 
at slaughter and found that 25% of recently calved dairy cows and 40% of dairy cows in late 
gestation had livers with visible evidence of fat accumulation, whereas less than 1 % of cows 
in other stages of lactation had such evidence. Reid (162) reported that 100% of clinically 
normal cows demonstrated histologically discernible fat in the liver in the first week 
postpartimi. and 63% of these cows had moderate to severe fatty liver. In addition. Reid et 
al. (163) estimated that one-third of high yielding dairy cow in the United Kingdom are 
affected by subclinical fatty liver. Based on histological data, he suggested that cows with 
less than 20% fat in the liver at one week after calving are considered normal and cows with 
more than 20% fat are considered to have fatty liver. Those percentages of fat were 
measiu"ed by using histologically stained sections, and the values are approximately twice as 
high as those determined by chemical assay. From the reported studies, it became obvious 
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that fatty liver occurs at a high incidence in periparturient cows. The adverse effects of fatt\ 
liver probably depend on the intensity of fat infiltration in the liver. 
Cows with extreme fatty liver usually show a poor health status in the immediate 
postpartal period. The cows usually have obese body conditions, and clinical signs of fatt> 
liver are complicated with the common postpartal diseases: metritis, mastitis, hypocalcemia, 
displaced abomasum. retained placenta, and ketosis. This situation is known as "fat cow 
syndrome" (138). Cows with fatty liver are leukopenic, with decreases in neutrophils, 
eosinophils, and lymphocytes (164) and show decreased fertility (118. 166). Treatments are 
usually ineffective, and prognosis is poor. 
The most common cases of fatty liver are subclinical. The cows have abnormal fan\-
infiltration without obvious clinical symptoms. The exact chronological pattern of liver fat 
accumulation in dairy cows is not clear with peak triacylglycerols (TAG) content in the liver 
occurring at near caving (87). one week (162), or two weeks (203) after calving. Gerloff et 
al. (71) reported that concentrations of liver fat increased during the late dry period and 
peaked within the first three weeks of lactation. The inconsistency may be caused by 
different frequencies of biopsy, or it may be related to differences in herd management or 
severity of fatty liver among herds. 
Fatty livers have roimded edges, and they are enlarged and discolored. Discoloration 
varies from a pale appearance in cases of mild fatty liver to a yellow-orange color in cases of 
severe fatty liver. In severe fatty liver, accumulation of TAG in parenchymal cytoplasm is 
accompanied by disruptions in hepatic structure, including fatty cysts in liver parenchyma, 
increased cell volume, compression of sinusoids, deceased volume of rough endoplasmic 
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reticulum, and mitochondrial damage. These morphological changes are all reversible, and 
there is no evidence of long-term damage to hepatocytes that results from fatty infiltration 
(138,163) 
Liver TAG concentrations are positively correlated with concentrations of serum 
NEFA (167), but not with serum and urine ketone body concentrations or with blood glucose 
concentrations (69). Serum activities of hepatocellular enzymes, including aspartate 
aminotransferase (AST), ornithine decarboxylase (OCT), y-glutamyl transferase, sorbitol 
dehydrogense, and iditol dehydrogenase, are usually increased in cows with fatty liver, and 
AST is the enzyme that has been best correlated with fatty liver (106. 88. 193. 208). Neither 
these enzymatic activities nor bromsulphthalein clearance test are reliable indicators for 
diagnosis of fatty liver (87). The most reliable method of diagnosis of fatty liver is liver 
biopsy followed by chemical analysis. 
Pathoohysioloev 
Three major predisposing factors for development of fatty liver are 1) overcondition 
or obesity during the dry period, 2) rapid weight loss around calving and in early lactation, 
and 3) high milk yield (71, 138, 163). Dry matter intake of obese dry cows is more likely to 
be depressed during the periparturient period (68, 165). Most high-producing cows are in 
negative energy balance in early lactation. All these factors would cause rapid body loss and 
increased plasma NEFA, which are precursors for hepatic TAG synthesis and closely 
associated with development of fatty liver in dairy cows. In addition, low serum insulin 
concentrations and increased lipolytic hormones such as grov^^ hormone, placental lactogen. 
L 
and prolactin during the periparturient period could promote mobilization of adipose TAG to 
provide additional energy and thereby increase plasma NEFA concentrations. 
De novo fatty acid synthesis does not occur in ruminant liver (17). Any NEF.A 
mobilized from adipose tissue are taken up by the liver from the plasma and can be either 
esterified to TAG, completely oxidized to CO^. or partly oxidized to ketone bodies. 
Oxidation and ketogenesis from NEFA in the liver have been discussed already. In 
nonruminants, rates of fatt\' acid esterification and secretion of TAG as very low densit}' 
lipoproteins (VLDL) increase simultaneously during periods of high fatty acid uptake (90). 
which, does not occur in ruminants. Secretion of TAG by hepatocytes from pregnant or 
lactating sheep is about 60% greater than by hepatocytes from nonpregnant sheep, but this 
was still less than 2% of fatty acid uptake, whereas oxidation accounted for about 12% of 
uptake (62). Rates of TAG formation in ruminant liver are similar to those in other species. 
TAG secretion, however, is very small but detectable in cows (157, 156). A direct 
comparison among species of TAG secretion rates from liver slices demonstrated a 
relationship between dependence on the liver as a site for lipogenesis and ability of the liver 
to secrete TAG (157). Grummer (81) proposed that ruminants may have evolved without the 
mechanisms necessary for high rates of VLDL secretion because of the limited precursors for 
TAG synthesis. Little research has been conducted to determine the rate-limiting step for 
TAG export in ruminants, and the reason for "an inherently slow rate of VLDL secretion" is 
not known. 
In vitro studies have shown that rates of fatty acid esterification were lower in 
hepatocytes from energy-restricted lactating goats (5). in the liver from feed-deprived 
lactating cows (55), or in the perfused liver from feed-deprived pregnant sheep (44). 
Recently, Van den Top et al. (203) found that activity of the enzyme for TAG synthesis, 
glycerolphosphate acyltransferase (GPAT), is significantly lower in fatty liver than in normal 
liver. This result confirmed earlier in vitro studies (5,44, 55) and suggests that low GPAT 
activity may divert fatty acids from esterification to p-oxidation or ketone bodies to protect 
hepatocytes against fiirther accumulation of TAG. 
Ketosis and fatty liver 
Ketosis and fatty liver have long been considered to be related metabolic disorders. 
The relationship between fatty liver and ketosis and the contribution of impaired 
carbohydrate and lipid metabolism toward the etiologies of these disorders, however, are not 
easy to elucidate because under field conditions it is hard to predict accurately which cows 
will succumb to these disorders. Spontaneous ketosis is usually accompanied by with fatty 
liver. Two lines of evidence indicate that fatty liver precedes ketosis. First, As already 
discussed, fatty liver is prevalent from calving to the first week postpartum, whereas cows are 
most susceptible to ketosis at three weeks postpartum. Second. A series of experiments from 
our laboratory also support the idea that fatty liver precedes ketosis, or more specifically, that 
ratios of TAG to glycogen in the liver greater than 2.5 seem to be required for occurrence of 
clinical ketosis (55). 
In summary, although the specific biochemical aberrations are unidentified, fatty liver 
results from excessive esterification of NEFA and a reduced TAG secretion rate from the 
liver. Ketosis probably results from increased ketogenesis because of decreased carbohydrate 
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status in the liver. The decreased carbohydrate status could result from either low substrate 
availability or low gluconeogenic capacity. As already discussed, it is still unclear whether 
fatty liver impairs the gluconeogenic capacity of the liver. The glucose deficiency theory- of 
ketosis is based on no defects of gluconeogenic enzymes and excessive gluconeogenesis in 
the liver (108). Gluconeogenic and ketogenic rates are both high in liver slices from early 
lactation cows (I). A liver with a high content of fat may divert fatty acids from 
esterification to P-oxidation (203) and may increase ketogenesis if the carbohydrate stams in 
the liver is low at the same time. This hypothesis agrees with the chronology of development 
of fatty and ketosis and with physiological and pathological states of cows in the 
periparturient period. 
Gluconeogenesis in Ruminants 
Introduction to regulation ofslucose homeostasis 
It is important to maintain relatively constant blood glucose concentrations. 
Therefore, the body must have precise mechanisms to regulate glucose production via 
gluconeogenesis and glycogenolysis, cellular uptake of plasma glucose, and utilization of 
glucose for glycogen synthesis and for glycolysis. The nutritional and hormonal regulation 
of processes involved in glucose metabolism has been an active area of research for decades, 
and mechanisms for homeostatic regulation of glucose in nonruminants have been clarified 
gradually (73, 91, 151, 152). Gluconeogenesis and glycolysis have many common reactions 
in their pathways except for three futile cycles: the glucose/glucose-6-phosphate cycle, the 
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fructose-6-phosphate/fructose-1.6-bisphosphate cycle, and the pyruvate/phosphoenolpyruvate 
cycle. Hepatic glucose production and utilization involve movement of substrates through 
these three cycles, so they are thought to be the major regulatory sites for glucose metabolism 
(Figure 1). Pilkis and Claus (152) divided hormonal regulation of glucose metabolism into 
short-term, which involve alterations in enzyme activity brought about by changes in 
allosteric effectors and phosphorylation/dephosphorylation of enzymes that can occur in 
seconds to minutes, and the long-term effects that involve changes in gene expression, a 
process that usually takes hours to days. 
In nonruminants, how gluconeogenesis is regulated during physiological states such 
as fasting, long-term starvation, diabetes, refeeding, and insulin or glucagon injections is well 
known. For instjince. for acute regulation of enzymatic activities during fasting, glucagon or 
a P-adrenergic agonist binds to its plasma membrane receptor and activates adenylyl cyclase, 
which results in increased inu^cellular cyclic adenosine monophosphate (cAMP) 
concentrations. Cyclic AMP activates protein kinase A (PKA). and PKA phosphorylates 6-
phosphofructo-2-kinase/fructose 2,6-bisphosphatase (PFIC-2/FBPase-2). a biftmctional 
enzyme. Therefore, the intracellular level of fructose 2.6-bisphosphate (Fru-2, 6-P2), which 
is a strong inhibitor of fructose 1, 6-bisphosphatase (FBPase), is decreased. Fru-2, 6-P, is 
decreased due to inhibition of 6-phosphofructo-l-kinase (PFK) and activation of FBPase. 
The decrease in Fru-2, 6-P2 inactivates pyruvate kinase (PK). both allosterically and by 
making the enzyme a better substrate for phosphorylation by PKA. These actions decrease 
PK activit}' and favor gluconeogenesis. On the other hand, after refeeding, insulin 
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Figure 1. Simplified pathways for gluconeogenesis (solid line) and glycolysis (dotted line) 
with an emphasis on regulatory sites in the liver. Gluconeogenic and glycolytic 
enzymes are indicated in boxes, and abbreviations are identified in text. 
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counteracts the stimulation of gluconeogenesis by glucagon and P-adrenergic agonists, 
probably by suppressing the rise in cAMP brought about by these hormones. Thus, insulin 
decreases the extent of phosphorylation of PK and PFK-2/FBPase-2 and decreases rates of 
gluconeogenesis. 
Hormones also exert important long-term effects on glucose metabolism by changing 
rates of enzyme synthesis. These effects are mediated through alterations of rates of mRNA 
synthesis and, in some cases, by changes in the rate of degradation of specific mRNA. Gene 
expression may be mediated at the mRNA translation level; however, no evidence exists for 
this in enzymes of glucose metabolism. Complete cDNA molecules have been cloned for all 
of the cytosolic enzymes involved in the three substrate cycles of hepatic glucose 
metabolism. These enzymes include glucokinase (GK). glucose 6-phosphatase (G6Pase). 
PFK, FBPase. PFK-2/FBPase-2. PEPCK, PK. and pyruvate carboxylase (PC). Extensive 
research has been done on nutritional and hormonal regulation of gene expression of some of 
these enzymes in nonruminants. In ruminants, however, studies on enzymatic regulation of 
gluconeogenesis are limited. One reason for this limitation is that no bovine hepatocyte cell 
line has been available, and primary cell cultvires of adult ruminant hepatocytes are difficult 
to maintain for unknown reasons. 
Significance of and methods to study pluconeosenesis in ruminants 
There are four major differences in glucose metabolism between ruminants and 
nonruminants. First, because most dietary carbohydrate is fermented in the rumen and only 
small amounts of glucose are absorbed directly from the gastrointestinal tract in ruminants. 
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90 to 100% of the glucose supply depends on a state of continuous gluconeogenesis. Second, 
in ruminants, gluconeogenesis increases after feeding when substrates are most plentiful, and 
it decreases during fasting. This is opposite to nonruminants where maximal gluconeogenesis 
occurs during fasting. Third, there are great demands in lactating cows for glucose, which is 
mainly used for synthesis of lactose in milk. Depending on the level of milk production, up 
to 80% of total glucose production could be used for milk production. Fourth, ruminants 
oxidized only limited amounts of glucose, and they use acetate instead of glucose for fatt>-
acid synthesis. Acetate and butyrate are important sources of energy that spare glucose. 
Because activities of hepatic GK are very low. it has been proposed that glucose utilization in 
ruminant liver is limited (14). From the four differences, it is obvious that gluconeogenesis is 
very important in ruminants for maintaining both plasma glucose concentrations and milk 
production. Some unanswered questions regarding gluconeogenesis and its regulation in 
lactating dairy cows are as follows: 1) How much glucose is synthesized in the liver per da\, 
and how much is derived from different gluconeogenic precursors? 2) How does 
gluconeogenesis change in different stages of lactation and in pregnancy? 3) How is 
gluconeogenesis regulated enzymatically? 4) How much is it affected by the availability of 
precursors and by hormones? To date, complete answers are not available for these 
questions, and some of the available research data are not consistent. 
Methods for studying gluconeogenesis in ruminants include in vivo whole body 
kinetic studies and in vitro studies such as liver slice incubations, recently established 
primary hepatocyte cultures, and determination of enz>'me activities. Two principal 
techniques have been used for quantitative estimates of rates of gluconeogenesis in vivo; 
isotope dilution and arterio-venous catheterization. The use of isotope dilution or tracer 
techniques allows measurement of the rate of turnover or irreversible loss of metabolites in 
steady-state conditions. Double-isotope techniques are useful to simultaneously measure 
glucose turnover, substrate turnover, and the incorporation of substrate into glucose. Arterio­
venous catheterization allows studies of individual organs in vivo. The in vivo techniques 
are not without disadvantages: for example, isotope dilution underestimates the 
gluconeogenic potential of a precursor because of label crossover in the TCA cycle. A 
relative new technique is the use of molecular biology tools to study metabolic regulation 
(74), but very little research has been done with this technique in ruminants. 
Gluconeosenic substrates 
Glucose is synthesized from propionate, glycerol, amino acids, and lactate. The 
contribution of each of these components to total gluconeogenesis is variable depending upon 
types of diet, amounts of diet, and physiological states of the animal. 
Propionate. The major gluconeogenic precursor in fed ruminants is considered to be 
propionate absorbed from the rumen. About 90% of absorbed propionate is taken up by the 
liver (24). Studies have shown that 27 to 60% of the total glucose utilization is synthesized 
from propionate in sheep (103. 113. 195). Wiltrout and Satter (212) showed that 45% of total 
glucose was derived from propionate in lactating cows. Glucose infusion caused a decreased 
rate of glucose production from propionate, but the percentage of propionate converted to 
glucose did not change, and exogenous glucose was more effective at decreasing glucose 
production from other gluconeogenic precursors than from propionate (103). Little glucose 
was derived from propionate in cows fasted for 4 days because it would onh' be absorbed in 
small quantities from the rumen (117) 
OlyceroL Glycerol is found primarily as the backbone of TAG in adipose tissue, and 
concentrations of glycerol in plasma ju-e low (23). Gluconeogenesis from glycerol is smzill in 
fed ruminants and contributes less than 5% of total glucose production (115). In fasted and 
ketotic sheep, however, up to 30% of irreversible loss of glucose was accounted for by 
glycerol (23). Ranaweera et al. (161) have shown that 13% of total glucose entry is derived 
from glycerol in normal pregnant sheep, 17% during starvation, and 91% during glycerol 
infusion. These data suggest that glycerol can be an important source of glucose production 
when its concentrations increase because of lipid mobilization during negative energy 
balance. 
Amino acids. Contributions of amino acids to gluconeogenesis also are variable, 
depending upon physiological and nutritional status. Individual amino acids used for 
gluconeogenesis, listed in descending order of contribution, are alanine, glutamate, aspartate, 
serine, and glycine (213). Wolff et al. (213) used in vivo kinetic techniques to estimate that 
11 to 30% of irreversible loss of glucose is derived from amino acids in fed sheep. Reilly et 
al. (168) reported a 28% contribution in cows, and Egan and Black (58) estimated that 
between 30 and 50% of glucose is derived from lactate, glycerol, and amino acids combined 
in maintenance-fed steers. Again, in vivo kinetic experiments often are difficult to interpret 
because of cross-over of labeled carbon atoms 
Lactate. Muscle and adipose tissue produce lactate endogenously, and it can be a 
significant product of soluble carbohydrate in the rumen. The liver and kidney normally are 
net users of lactate. Lindsay (115) estimated tiiat lactate contributed 28% of total glucose, 
which is after correction for crossover of carbon from lactate. Studies with fed sheep showed 
only a 4 to 10% contribution of lactate to glucose (24). but in starved sheep there was about a 
15% contribution of lactate (4). The fraction of lactate turnover converted to glucose has 
been calculated to be 30 to 40% in pregnant sheep and lactating cows, but it was only 10% in 
lactating sheep and 27% in pregnant cows (12). In addition, the glucose-lactate 
interconversion, namely the Cori cycle, seems to be lower in ruminants than in other species 
(12). 
Nutritional and enzymatic resulation of eluconeoeenesis 
Because glucose metabolism differs between ruminants and nonruminants. regulators' 
mechanisms may also differ, but the mechanistic nature of the differences has not been 
clearly elucidated. In general, gluconeogenesis is controlled by substrate availability and by 
rate-limiting enzyme activities. 
The availability of substrates is a major factor determining the rate of 
gluconeogenesis (115). Positive correlations between digestible energy intake and glucose 
entry rates have been reported by Leng (112). Lindsay (114), Steel and Leng (195), Herbein 
et al. (86), Schmidt et al. (183), and Yost et al. (216). Rates of glucose synthesis in sheep 
were increased by nominal infusions of propionate and casein, and it was suggested that the 
rate of gluconeogenesis be related directly to the availability of gluconeogenic precursors 
absorbed from the digestive tract (102). Veenhuizen et al. (205) fed propionate at 6.3 mol/d 
to steers and found an increase of 1.3 mol/d in glucose production. Gluconeogenesis 
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decreases when substrate availability becomes limiting. Lindsay (114) reponed a 33% 
decline in glucose production after a 24-h fast and Katz and Bergman (104) reported a 50% 
decline in glucose production in sheep fasted for three days. 
The results of in vitro measurements of activities of gluconeogenic enzymes in 
ruminant livers from studies in the 1960s and 1970s varied from each other and also differed 
from activities in the liver of nonruminants. Activity of PC increased during fasting in sheep 
(64) and in lactating cows (16). Baird et al. (13) showed that PC activity increased in 
spontaneously ketotic cows, whereas Ballard et al. (16) did not detect the increase. In 
diabetic sheep, significant increases in PC and PEPCK activities were shown by Filsell et al. 
(64). Administration of dexamethasone caused a significant decrease in PC activity in sheep 
(64). but no changes were found in lactating cows (10). Glucagon infusion in sheep caused 
an increase in PC activity without changes of PEPCK. FBPase. and G6Pase (31). Compared 
with nonlactating cows, PC activity (16) and FBPase (132) activity in lactating cows are 
significantly greater. Similarly in sheep. Smith et al. (192) has shown that PC activity 
increased 5- to 7-fold and FBPase activity increased two fold during late pregnancy and in 
early lactation when compared with nonpregnant sheep. Smith et al. (1982) also found that 
PFK activity decreased by 50% during lactation, that PK activities declined by about 40% at 
the end of pregnancy, and that PK activity is very high in sheep. These results suggested 
decreased recycling of fructose-6-phosphate and phosphoenolpyruvate and enhanced 
gluconeogenic capacity in late pregnancy and early lactation in sheep. 
Only one study has shown a significant decrease in PEPCK activity in fasting 
lactating cows (14). During starvation, no significant changes were found in PEPCK 
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activities in sheep (64), lactaiing cows (16). or Holstein heifers (217). Also, no significant 
changes have been found in spontaneously ketotic cows (13. 16). Dexamethasone caused a 
significant decrease in PEPCK activity in spontaneously ketotic cows (11) and in normal 
lactating cows (10). All-concentrate diets caused a 24% increase in PEPCK activity in 
lactating cows (10), but no change in steers (217). Activities of PK decreased significantly in 
fasting lactating cows (14). and in spontaneously ketotic cows (11). No changes were found 
in FBPase and G6Pase activity in spontaneously ketotic cows (13). but these two enzymes 
increased significantly in fasting sheep (64). 
Regulation of Expression of the PEPCK Gene 
To date, little research has been conducted on regulation of gene expression of 
enzymes of glucose metabolism in ruminants. Research for this dissertation mainly involves 
mRNA expression of PEPCK, and briefly of PC and FBPase in dairy cows. Therefore, 
selective review focusing on studies of PEPCK in nonruminants. together with a brief 
overview PC and FBPase. will now be presented. 
The enzyme 
Phosphoenolpyruvate carboxykinase (OTP) (EC 4.1.1.32) is one of the most 
extensively studied enzymes, and it was reviewed recently by Hanson and Patel (83). 
PEPCK catalyzes the decarboxylation of oxaloacetate to phosphoenolpyruvate, utilizing GTP 
as the phosphate donor. Utter and Kurahashi (201) first discovered PEPCK in 1953. There 
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are two forms of PEPCK in mammalian tissues, the mitochondrial (PEPCK-M) and the 
cytosolic form (PEPCK-C). Relative ratios of the two forms vary among species. In rats, 
mice, and hamsters, 90% of the hepatic PEPCK is found in the cytosoi. In the liver of adult 
birds, all PEPCK activity is PEPCK-M. In humans and dogs, half of the total PEPCK 
activity is located in the cytosoi and half in mitochondria, respectively. In general, the 
relative proportions of PEPCK-C and PEPCK-M in an animal are the same in all tissues. In 
chickens where PEPCK-C is absent in the liver of adult birds, however, it represents about 
half of the total PEPCK activity in the kidney (190). In sheep. 70% of the total PEPCK 
activity was found in cytosoi and 30% was in mitochondria (198). 
Wiese et al. (210) presented data on the intracellular distribution and/or activity of 
PEPCK isozymes in several tissues from rabbits, guinea pigs, rats, chickens, and pigeons. 
High PEPCK activities are found in liver and kidney of all species, in brown adipose tissue of 
rats, and in gastrointestinal mucosa of rabbits. Low activities of PEPCK are found in skeletal 
muscle of all species that were tested, and PEPCK was essentially undetected in brain, 
spleen, lung, and heart of all species. High PEPCK activity also was found in mammary 
tissue during lactation (101). PEPCK-M has a long half-life of about 60 h and is 
constitutively expressed, whereas PEPCK-C from rat liver, whose concentrations are 
regulated acutely by diet and hormones, has a half-life of about 8 h (94). PEPCK-C in liver 
and kidney is known to be important in gluconeogenesis. while the physiological role of 
PEPCK-M is uncertain (210). PEPCK in liver and adipose tissues was suggested to be 
involved in glyceroneogenesis for reesterification of free fatty acids during starvation (15). 
The roles of PEPCK in other tissues are not defined. 
The gene for PEPCK-C from rats has 10 exons and 9 introns with a total length of 6.0 
kb. which encodes 621 amino acids contained in PEPCK-C with a MW of 69.289 KDa (22). 
In general, the species variants of PEPCK-C have considerable sequence identity. PEPCK-C 
and PEPCK-M from chickens are encoded by separate nuclear genes of very different sizes, 
and their cDNAs have about 60% sequence identity. PEPCK-M consists of 607 amino acids 
(207). The cDNA for PEPCK-M from human liver has been cloned recently (137). Overall, 
it had a 68% DNA sequence and 70% deduced amino acid sequence identity with the human 
PEPCK-C cDNA. It also had an opening frame of 1920 bp. which is 54 bp longer than that 
of human or rat PEPCK-C cDNA. However, the PEPCK-M mRNA is 2.25 kb long, which is 
about 0.6 kb shorter than mRNA of PEPCK-C. 
A notable property of PEPCK is the requirement for thiol reagents such as P-
mercaptoethanol or dithiothreitol for maintaining the active form of the isolated enzyme. 
PEPCK utilizes a divalent metal ion bound in the activation site of the enzyme as an 
activator, and a second divalent cation. Mg"*. is associated with OTP, the substrate (6). In 
general, the concentration of critical substrates such as oxaloacetate and GTP. as well as the 
availability of metal ions are thought to be important factors in determining the short-term 
regulation of PEPCK, but to date. PEPCK has no known allosteric regulators. Therefore, the 
regulation of PEPCK activity occurs primarily at the transcriptional level (76.110.181) and/or 
mRNA stability (92). 
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General information about sene expression 
The half-life for PEPCK-C mRNA in rats is approximately 30 min. so that changes in 
the transcription rate of the gene have a marked effect on the rate of enzyme synthesis (140). 
It is well known that a number of factors, including diet, hormones, changes in acid/base 
status, and specific chemical compounds, can alter concentrations of PEPCK-C by changing 
its rate of synthesis. Most studies were done by using primary cell cultures, hepatoma cell 
lines, or liver, kidney, and adipose tissues of rats. Table 1 presents a list of factors that alter 
concentrations of PEPCK-C together with their known sites of action on expression of the 
PEPCK-C gene. It is unlikely that such diverse effectors have independent sites of action on 
expression of PEPCK-C. Numerous factors often act indirectly, and it seems likely that they 
interact at one or more of the critical regulation sites of ±e PEPCK-C gene promoter or on 
mRNA stability. 
The known control mechanisms will be reviewed in detail later. The control patterns 
for PEPCK-C in various tissues are similar, but there is a different rate of response to these 
factors, and some effects may be tissue-specific. One exception is the effect of 
glucocorticoids, which increase the activity of hepatic PEPCK-C but decrease the synthesis 
rate of the enzyme in adipose tissue (133) and in 3T3-F442A adipose cells (67). 
Mechanisms of transcription regulation 
The nutritional and hormonal transcriptional regulation of the PEPCK-C promoter is a very 
complex process, and only known mechanisms elucidated from some key studies are 
reviewed here. Several approaches have been used to study these mechanisms. Introduction 
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Table 1. Factors that alter concentrations of PEPCK-C in mammalian tissues ' 
Factors Tissue Mechanism of Action 
Increase Concentrations 
Glucagon (cAMP) liver, adipose tissue transcription. mRNA 
stabilization 
kidney (less effective than in transcription. mRNA 
liver stabilization 
Glucocorticoids liver, kidney transcription. mRNA 
stabilization 
Thyroid hormone liver transcription 
Catecholamines liver, adipose tissue enzyme synthesis 
Prolactin liver, mammary gland enzyme synthesis 
Metabolic acidosis kidney transcription. mRNA 
stabilization 
Glucose-free diet or fasting liver transcription 
High-density cell culture H4IIC3 hepatoma cells transcription 
Diabetes liver, kidney, adipose tissue transcription 
Serotonin liver, kidney, small intestine mRNA 
Retinoic acid hepatocytes transcription 
Vanadate (low concentration) ob/ob mice (low PEPCK mRNA 
activity). H35 hepatoma cells 
Leptin H4IIC3 hepatoma cells mRNA 
fatty acids 3T3-H442A adipocyte transcription 
Decrease concentrations 
Insulin liver, adipose tissue, kidney transcription 
Glucocorticoids adipose transcription 
High dietary glucose liver, adipose tissue transcription 
Glucose H4IIEC3 hepatoma ells mRNA 
Vanadate (high concentration) hepatoma cells transcription 
Lithium liver transcription 
Phorbol ester hepatoma cells transcription 
Ochratoxin kidney mRNA 
Liver regeneration liver transcription 
Redox state liver transcription 
Cyclosporin A kidney transcription 
Epidermal growth factor hepatocytes mRNA 
Tumor necrosis factor hepatoma cells mRNA 
Inositol phosphoglycan hepatocytes mRNA 
Interleukin-6 liver transcription. mRNA 
stabilization 
Age hepatocytes, liver transcription 
' Modified from Hanson et al. (83), p. 228. 
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of chimeric genes which contain the PEPCK promoter linked to a reporter gene, into cells in 
culture was used to determine the sequences responsible for control of transcription (158. 
123. 191.214). Transgenic mice, into which PEPCK-bGH (bovine growth hormone) genes 
were introduced, were generated to smdy tissue and developmental-specific regulation of the 
gene (131). A number of protein binding domains in the PEPCK promoter have been 
identified by DNase I footprinting analysis (169, 191) and gel mobility shift analysis (116). 
In these smdies, specific block mutations and site-directed mutagenesis were introduced into 
the PEPCK promoter to determine functions of specific genetic elements. The majority of 
regulatory sites are located in a region between -500 to +73 of the PEPCK-C promoter. 
However, Ip et al. (98) have identified an enhancer element in the PEPCK-C promoter at 
-4800. which is involved in the high level of tissue-specific expression of the PEPCK-C gene 
in the liver. This element binds a nuclear protein, hepatic nuclear factor-3. Table 2 presents 
a summary of the current information on the regulatory elements contained in the PEPCK-C 
promoter, together with the transcriptional factor(s) that bind to these elements. 
cAMP. As shown in Table 2, several cis-acting sequences within the PEPCK-C 
promoter mediate cAMP activity. The presence of a cAMP regulatory element (CRE) in the 
PEPCK-C gene was first suggested by Short et al. (191). The consensus sequence. 
TTACGTCA, which maps between -90 and -83 of the PEPCK-C promoter, was identified as 
CREl by Boker et al. (28). PEPCK-C promoter also contains the CRE2 site, which has a C 
to G substitution at -87 of CREl. The upstream CRE weakly binds nuclear protein extracted 
fi-om the liver (169). The CRE of PEPCK-C acts in concert with upstream elements that 
regulate transcription of the gene by cAMP. A block mutation in either the 
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Table 2. Summary of regulatory domains in the PEPCK-C promoter' 
Binding site Location Sequence Binding protein Function in 
transcription 
TATA -29/-23 TATTTAAA TBP basal 
CRE-1 -91/-84 TTACGTCA C/EBPP, basal 
CREB, Fos/Jun. transcription/cAMP 
DBP 
PI -116/-104 TGGCTATGACCA NF-l/CTF basal 
CRE-2 -I44/-137 TTAGGTCA C/EBP cAMP 
P2 -190/-185 ATTAAC HNF-1 renal expression 
P3(I) -243/-235 TTGTGTAAG C/EBPp. DBP hepatic 
expression/cAMP 
P3(II) -25S/-252 TTAGTCA Fos/Jun basal. cAMP 
P4 -282/-274 ATCAGCAAC C/EBPp basal. cAMP 
TRE -332/-316 TGGGGGTCAAG TR thyroid hormone 
GACAGG 
GR2 -363/-353 CATATGAAGTC GR glucocorticoids 
P5/GR1 -385/-374 ACACAAAATGTG GR glucocorticoids 
IRE/AF2 -41 MOO TGGTGTTTGACA unknown insulin. 
AC glucocorticoids 
P6/AF1 -450/-436 ATGACCTTTGGC unknown glucocorticoids 
CGT 
' Taken from Hanson et al. (83), p. 235. 
CREl or P3(I) decreases transcription by 70%. but simultaneous mutation of both elements 
completely eliminates transcriptional activation of PEPCK-C promoter by cAMP (116). To 
date, only members of the leucine zipper family of transcriptional factors [i.e.. cAMP 
regulatory element binding protein (CREB), CAAT/enhancer binding protein (C/EBP), D-
binding protein (DBP), and Fos/Jun dimers] are known to bind to CRE and to induce 
transcription from the PEPCK-C promoter when their genes are cotransfected and expressed 
in hepatoma cells (146. 170). Recently. Roesler et al. (171) demonstrated that C/EBPa is 
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required for mediating cAMP responsiveness of the PEPCK promoter, although the DNA 
binding domain of C/EBPa was not required for this activity in hepatoma cells. 
Insulin. Insulin has been suggested by Granner et al. as the "dominant negative 
regulator" of PEPCK-C gene expression because of its ability to inhibit transcription of the 
PEPCK gene in hepatoma cells in the presence of cAMP and glucocorticoids (181) and to 
decrease the basal level of transcription of the gene (76). Despite the strong effects of insulin 
on PEPCK-C gene transcription, delineating the insulin response elements in the PEPCK-C 
gene has been elusive. The activity of insulin to block, the inductive effect of cAMP on 
transcription from the PEPCK-C promoter in cells transfected with chimeric genes, in most 
cases, has not been demonstrated (214). Finally, an insulin regulatory sequence (IRS). 
TGGTGTTTTG, between -416 and -407 of the PEPCK-C promoter has been described by 
O'Brien et al. (143). They reported that a mutation in the core IRS sequence of the PEPCK 
promoter resulted in approximately 50% inhibition of the ability of insulin to block 
expression of the PEPCK-C AT gene in the presence of both cAMP and glucoconicoids. 
Because of the dominant role of insulin, it is possible that there are additional elements 
within the PEPCK-C promoter or other mechanisms involved in the transcriptional effect of 
insulin. By similar approaches, O'Brien et al. (142) found that phorbol ester also inhibits 
PEPCK-C gene transcription through the IRS as does insulin. 
By using in vitro run-on assays with specific probes directed against regions on the 
PEPCK-C gene, Sasaki and Granner (180) analyzed whether transcription proceeds 
uniformly across this gene in response to insulin and cAMP. The primary transcript of 
PEPCK was synthesized at a rate of about 2500 nucleotides per minute in the presence of 
cAMP but decreased to 1000 nucleotides per minute when insulin was present. These results 
suggested that both insulin and cAMP exert their primary effects directly at the level of 
transcriptional initiation, but in opposite directions. Sutherland et al. (197) recently found 
that wotmannin, an inhibitor of phosphatidylinositol 3-ldnase (PI3K). blocks the inhibition 
by insulin of glucocorticoid- and cAMP-stimulated PEPCK-C gene transcription. In contrast, 
wotmarmin does not block the similar effects of phorbol esters. Gabbay et al. (70) 
demonstrated that neither insulin nor phorbol ester regulation of PEPCK-C gene transcription 
requires activation of the Ras/MAP kinase pathway. These studies suggested that PI3K is 
required for the regulation of PEPCK gene transcription by insulin but not by phorbol esters. 
Glucocorticoids. Glucocorticoids have long been thought to have a permissive action 
on gluconeogenesis. The additive effect of glucocorticoids on PEPCK gene expression was 
first demonstrated in 1982 by Salavert and lynedjian (174), who reported that glucagon had 
only marginal stimulatory effects on the synthesis of PEPCK-C in hepatocytes in the absence 
of dexamethasone. Two regions of the PEPCK-C promoter; one distal between -1264 and 
-1111 and the other more proximal between -468 and -420 (glucocorticoid response unit. 
GRU) have been implicated in the regulation of PEPCK gene transcription by 
glucocorticoids (97). GRU contains two glucocorticoid receptor-binding sites (GRl and 
GR2) and two accessory factors (API and AF2). Interestingly. IRS is found within the AF2 
site. Recently, Imai et al. (96) demonstrated that maximal induction of transcription from the 
PEPCK-C promoter by glucocorticoids required both the CRE and the GRU; they also noted 
an interaction between the glucocorticoid receptor and CREB, suggesting that these proteins 
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could be involved in the control of PEPCK gene transcription. This also could explain the 
additive effects of cAMP and glucocorticoids in stimulating PEPCK gene transcription. 
Diabetes and diet. The use of PEPCBC-bGH transgenic mice provided further 
information on dietary and hormonal regulation of PEPCK gene expression, as well as 
information on PEPCK gene expression in diabetes. PEPCK activity (47). protein (183). and 
mRNA (186) are all increased in animal models of noninsulin dependent diabetes mellitus 
(NIDDM) and streptozotocin-induced diabetes. An analysis of the regulatory elements in the 
PEPCK-C promoter involved in the response of the PEPCK-C gene to diabetes has been 
carried out by using transgenic mice with a deletion in the GRU region of the PEPCK-C 
promoter and a mutation in the CRE and P3(I) regions (66). Removal of GRU eliminated the 
induction of transcription of the PEPCK-bGH gene in the liver of diabetic mice, and 
adrenalectomy of diabetic mice also eliminated the induction of hepatic PEPCK-C mRNA. 
Mutation of CREs of the PEPCK promoter did not limit induction of PEPCK transcription by 
diabetes. These results suggested an important role for glucocorticoids in the regulation of 
PEPCK-C gene transcription during diabetes. 
Acute and marked dietary regulation of PEPCK gene transcription is another 
important feature of the PEPCK-C gene (110. 131). Dietary regulations are usually thought 
to be mediated via changes in concentrations of glucagon (via cAMP) and insulin in plasma. 
Surprisingly, studies using transgenic mice have shown that this is not the case. Patel et al. 
(147) found that removal of both CREl and P(I) domains, either singly or in combination, 
did not inhibit the induction of PEPCK-bGH gene expression in the liver of transgenic mice 
fed a carbohydrate-free diet. These results indicated that conventional cAMP regulatory 
elements are not directly involved in the induction of PEPCK-C gene transcription caused b\ 
carbohydrate-free diets or diabetes. IRS is also not involved in negative effects of 
carbohydrate feeding on PEPCK gene transcription because its deletion did not prevent the 
inhibition of expression of PEPCK-bGH gene in the liver of transgenic mice fed a high-
carbohydrate diet (66). Davies et al. (51) recently showed that concentrations of 
phosphorylated CREB were decreased significantly in the liver of diabetic rats and that 
insulin treatment reversed this effect. That study also showed that overexpression of PEPCK 
is not linked to the cAMP signaling system. The PEPCK-C gene promoter in patients with 
NIDDM was examined recently, and no DNA sequence polymorphisms were found in an\" 
patient (120). This suggests that mutations in cis-acting PEPCK gene regulatory elements do 
not constitute a common cause of NIDDM. 
PC and FBPase 
In contrast to PEPCK. hormonal and nutritional regulations of the PC and FBPase 
genes are poorly understood. Pyruvate carboxylase (EC 6.4.1.1.) is a biotin-containing 
enzyme that catalyses the carboxylation of pyruvate to form oxaloacetate for gluconeogenesis 
and replenishing intermediates of TCA cycle for fatty acid, amino acid, and neurotransmitter 
synthesis. The native enzyme consists of four identical subunits arranged in a tetrahedron­
like structure. Mammalian PC is regulated allosterically by acetyl-CoA. which stimulates the 
cleavage of ATP in the first partial reaction and induces a conformational change in the 
tetrameric structure of the enzyme (7). Recently, cDNA for PC has been cloned and the 
deduced amino acid sequence has been determined for mice, rats, and humans (100. 121. 
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219). There is a high degree of amino acid identity among these species, and the size of 
mature PC mRNA is 4.2 kb in all three species. Northern blotting analysis showed that PC 
mRNA is highly expressed in liver, kidney, adipose tissues, and brain; moderately expressed 
in heart, adrenal gland, and lactating mammary gland; and expressed at a low level in spleen 
and skeletal muscle in rats (100). Few studies have been done on hormonal regulation of the 
PC gene. One study with 3T3-L1 cells showed that both PC activity and PC mRNA were 
decreased markedly by cAMP alone or together with insulin in these cells, but the amount of 
PC protein was not changed (220). In contrast to being exclusively a mitochondrial enzyme 
in most species, PC in ruminants is found in both cytosol and mitochondria. Acetyl-CoA. 
propionyl-CoA, and butyryl-CoA are all activators of PC in ruminants (17). 
Fructose 1.6-bisphosphatase (EC 3.1.3.11) catalyzes the hydrolysis of Fru-2. 6-P, to 
fructose 6-phosphate and inorganic phosphate in gluconeogenesis. The enzyme, a tetramer of 
four identical polypeptide chains, is subjected to both acute and long-term hormonal 
regulation. The activity of FBPase is regulated allosterially by AMP and by Fru-2.6-P, 
which is a potent inhibitor of FBPase. Fru-2,6-P2 has been postulated to bind either the 
active site (153) or a separate allosteric site (204). Concentrations of Fru-2. 6-P, are strictly 
regulated by PFK-2/FBPase-2, which is regulated by phosphorylation/dephosphorylation and 
by gene expression of hormonal control (49,154, 172). 
The cDNA for FBPase has been cloned from pigs, rats, and humans, and the primary 
sequence of deduced amino acids of the enzyme is highly homologous among these species 
(59. 211). FBPase is also under long-term regulation by change in concentrations of the 
enzyme, which increases in livers from diabetic and fasted rats. FBPase mRNA was 
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increased 10-fold in the liver from diabetic rats and decreased to control levels after 24 h of 
insulin treatment, but the decreases in FBPase mRNA upon insulin treatment were slower 
relative to PEPCK mRNA (59). Also, FBPase mRNA in primary rat hepatocyte cultures was 
increased by cAMP and decreased by insulin (60). By using Northern blotting with a rat 
liver cDNA, FBPase mRNA was detected only in the liver and kidney of rats (59). although 
significant activities of FBPase existed in brain and muscle. The size of rat FBPase mRNA 
was about 1.4 kb of single species, and its half life was 5 to 6 h (60). 
Glucagon in Ruminants 
History and metabolic effects of slucaeon 
Glucagon was discovered in 1923 after Kimball and Marlin succeeded in separating 
the hyperglycemic factor from the hypoglycemic component of the crude extracts of canine 
pancreatic tissue (107). Glucagon was purified in crystalline form by Staub et al. in 1955 
(194), and linger developed a radioimmunoassay for glucagon that made it possible to 
measure its concentration in the plasma of dogs and humans (200). 
The preproglucagon gene, located on the long arm of chromosome two. is expressed 
in pancreatic a-cells, small intestinal L-cells, and certain hypothalamic cells. These cells 
produce different kinds of glucagon-like polypeptides. Only the pancreatic a-cells have the 
enzymes to cleave proglucagon to "true glucagon", a 29 amino acid polypeptide. The amino 
acid sequence of glucagon is the same in all mammals studied, except the guinea pig, so 
glucagon exhibits a high degree of conservation. 
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Metabolic effects of glucagon have been studied extensively in dogs and humans by 
using various infusion techniques, i.e., pharmacological, supraphysiological. or physiological 
doses of glucagon together with somatostain clamps or diabetic models. A vital 
physiological role of glucagon is increasing hepatic glucose production for maintaining 
glucose homeostasis. Glucagon increases both glycogenolysis and gluconeogenesis in 
nonruminants. The effect on glycogenolysis is time-dependent, i.e., initial and transitory-, but 
the effect on gluconeogenesis is time-independent (48). Glucagon increases gluconeogenesis 
via promoting hepatic uptake of amino acids and increasing activities of key gluconeogenic 
enzymes. Decreases in concentrations of plasma amino acids are common during 
hyperglucagonemia. Contributions of glucagon to postabsorptive glucose production can be 
confirmed by glucagon immimoneutralization by using a high-affinity monoclonal glucagon 
antibody. Plasma glucose was decreased in normal rabbits and decreased even more in 
alloxan-induced diabetic rabbits by glucagon immunoneutralization (29). 
Both in dogs and humans, glucagon increases lipolysis in adipose tissue (111), 
especially when plasma insulin concentration is controlled to be normal or during moderate 
hyperglucagonemia in humans (45). During short-term hyperglucagonemia. degradation of 
protein was not changed (65); yet, it is not known whether protein degradation increases 
during long-term hyperglucagonemia. 
The known metabolic effects of glucagon in ruminants were evaluated primarily by 
Brockman et al. (32, 43). Glucagon was clearly shown to increase hepatic glucose 
production and gluconeogenesis in sheep by arterio-vemous catheterization and tracer 
techniques. Glucagon increased hepatic uptake of alanine, glutamine, other amino acids, and 
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lactate, but not glycerol (43). Also. Brockman (37) showed that utilization of propionate 
seemed not to be regulated by insulin or glucagon. However, other in vitro studies indicated 
that glucagon may enhance the conversion of propionate to glucose (50, 182). 
Infusion of glucagon has increased plasma glycerol when glucagon-stimulated insulin 
release was prevented, an effect that implies that glucagon increases lipolysis (33). In normal 
sheep, however, hyperinsulinemia prevented this increase, and concentrations of plasma 
NEFA actually decreased during infusions of glucagon (19). Further, glucagon showed no 
lipolytic effects in vitro in studies of adipose tissue from sheep and dairy steers (63). 
Therefore, the presence of a lipolytic effect of glucagon is still questionable in ruminants. To 
date, few known studies have been done on glucagon effects in dairy cows. 
Control of sluca^on secretion 
Release of glucagon fi'om the pancreas varies depending on nutritional and 
physiological status, stress, and pathological status. Glucagon secretion is controlled by 
nutrients and metabolites, hormones, and the autonomic nervous system. Extensive research 
has been done on glucagon release in nonruminants. but the current review mainly 
summarizes studies in ruminants. 
Glucose. Infusion of a 20% glucose solution into the duodenum of steers caused a 
decrease in plasma glucagon concentrations (25). Intravenous infusion of glucose into 
normal sheep also decreased glucagon concentrations (21, 34. 39). In dairy cows, 20 min of 
intrajugular glucose infusion cause a significant decrease of plasma glucagon concentrations 
(178). Low glucose concentrations resulting from starvation, alcohol infusion, insulin 
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administration, or blockage of glucose uptake by 2-deoxyglucose stimulate the a-cells to 
release glucagon. Bloom et ad. (27) have shown that injection of 2-deoxyglucose into calves 
could increase glucagon concentrations. 
Amino acids. Amino acids stimulate the release of glucagon. The gluconeogenic 
amino acid, alanine, is a strong a-cell secretagogue. but so are certain nongluconeogenic 
amino acids such as arginine (139. 144). Abomasal infusion of protein into sheep (18) and 
duodenal infusion of amino acids into steers (26) caused an increase in plasma glucagon 
concentration. Serine, lysine, aspargine. alanine, and glycine stimulated glucagon release b\ 
pancreatic slices from lambs, with glycine and alanine being the most stimulating amino 
acids (20). Also, intravenous infusion of 17 amino acids in sheep, each at a dose of 3 
mmol/kg over 30 min. indicated that alanine, glycine, and serine induced a greater 
enhancement of both glucagon and insulin secretion than did other amino acids (109). 
Leucine was the most effective amino acid in stimulating insulin secretion, but it did not 
increase in glucagon and growth hormone secretion. No amino acid was able to specificalh 
stimulate glucagon secretion without also increasing secretion of insulin or growth hormone 
(109). Amino acid release during protein digestion probably accounts for the glucagon 
increment that occurred in sheep after feeding (21) and in grain-fed steers (26). Because a 
high glucagon concentration causes a decrease in plasma amino acids (127). the relationship 
between amino acids and glucagon may reflect a physiological feedback. 
Volatile fatty acids (VFA). In ruminants, VFA firom carbohydrate fermentation in the 
rumen are the most important energy sources for the body, and research suggests that VFA 
play a role in the control of glucagon secretion. Earlier studies have shown that 
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supraphysiological doses of VFA stimulate the release of insulin and glucagon from the 
pancreas (21. 53. 95. 125). However, the effects of physiological levels of VFA on release of 
these hormones have been controversial (53, 196). Physiological infusions of butyrate. but 
not propionate, increased glucagon concentration (38). However, other studies have shown 
that infusion of propionate at a physiological rate through either a mesenteric vein or a 
femoral vein increased concentrations of plasma insulin and glucagon (150,176. 177). Mineo 
et al. (135) did a smdy to investigate chemical specificity of VFA in stimulating insulin and 
glucagon secretion in sheep. N-butyric acid was the most effective for both insulin and 
glucagon secretion among the VFA tested. Long-chain free fatty acids were associated with 
a decreased glucagon concentration during fasting in sheep (46). 
Insulin. In sheep, insulin infusion stimulates glucagon secretion, but effects seem to 
be mediated via hypoglycemia because simultaneous infusion of glucose negated any 
increases in glucagon (34). Actually, the relationship between insulin and the role of plasma 
insulin and/or glucose in the control of glucagon secretion has not been elucidated clearly. 
Because hyperglucagonemia is a hallmark of both Type I and Type II diabetes in humans, 
extensive studies have been done to investigate the role of insulin and glucose in regulating 
glucagon secretion. Since Samols et al. (175) discovered in 1965 that insulin was a powerful 
inhibitor of glucagon secretion, several in vitro and in vivo studies have supported their 
conclusion. A study that used isolated a-cells, however, showed that insulin was unable to 
affect glucagon secretion (155). An in vivo study in alloxan-induced diabetic dogs failed to 
demonstrate a direct role of insulin in controlling glucagon secretion (78). A recent study 
also showed that plasma glucagon concentration did not change in hyperinsulinemic 
euglycemic rats (122). Moreover, expression of the glucagon gene was insensitive to 
changes in concentrations of plasma glucose and insulin (122). In contrast to the 
controversial effects of insulin on glucagon, glucagon definitely has a stimulatory effect on 
insulin secretion (175). This stimulation may be achieved indirectly by glucagon increasing 
glucose production, which in turn increases insulin secretion. On the other hand, Ohenda 
found that C-terminal peptides of glucagon enhanced insulin release and that glucagon 
peptide 21-29 is the minimal structure among the C-terminal glucagon fi^gments to stimulate 
insulin secretion (145) 
Gastrointestinal hormones and the autonomic nervous system. The use of 
phentolamine in exercised sheep was associated with an increase in insulin concentration and 
seemed to delay the exercise-induced increase in glucagon. Also, administration of 
propranolol had no effect on glucose turnover or on concentrations of plasma glucagon and 
insulin. These results suggested a-adrenergic mediation of the sympathetic influence on 
insulin and glucagon secretion (35, 36, 41. 42). Epinephrine stimulates glucagon secretion 
and inhibits insulin secretion (19), which suggests a role for these hormones during stress. 
Physiological and pathological states and stress. Bassett et al. (21) has shown that 
glucagon concentration peaks 2 to 4 hours after feeding, but a postprandial increase is not 
always observed (17). Glucagon concentrations usually decreased during fasting (21,46), 
but they sometimes remained imchanged (75). Plasma glucagon concentrations were 
significantly greater in sheep given a low-energy diet compared with those given a high-
energy diet (141). However, in prepartal cows, there were small variations and no influence 
of feeding on glucagon levels, but there was a strong increase after calving, especially in the 
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cows fed the highest amounts of concentrates (93). Glucagon concentrations were similar 
throughout lactation, and above average milk production was associated with greater 
glucagon, less insulin, and lower concentrations of plasma glucose (85). Other smdies. 
however, showed opposite results. Glucagon concentrations tended to be greater in low-
producing cows than in high-producing cows (21) and tended to increase as milk production 
decreased (84). Glucagon concentration tended to increase (124) or to be greater in early 
lactation (148). 
Plasma glucagon concentrations in ketotic cows also have not been consistent. 
Hyperketonemic cows had lower insulin and higher glucagon concentrations than normal 
cows (93). Sasaki et al. (179) also reported that blood glucagon increased significantly in 
spontaneously ketotic cows. Simultaneous injections of insulin and glucose caused plasma 
glucagon to decrease and insulin to increase, which resulted in a more efficient treatment of 
ketosis than injection of glucose alone (179). However, in experimentally ketotic cows, 
deBoer et al. (52) found that plasma glucagon concentrations decreased from 3 wk 
postpartum to the experimentally induced ketonemic period. A similar decrease was 
observed in spontaneously ketotic cows, although secondarily ketotic cows had increased 
concentrations of glucagon (25). 
Summary. Although some information exists, results of studies on glucagon levels in 
fed and fasted states as a flmction of energy level of the feed, stage of lactation, and ketosis 
are not consistent. Because digestion and absorption in adult ruminants are prolonged when 
compared with nonruminants and because the feeding and management system is less 
consistent in ruminants, the effects of dietary influences and diurnal patterns on glucagon 
J 
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levels are more complex. Another important reason for inconsistent results is that there have 
been some methological difficulties in the measurement of plasma glucagon by 
radioimmunoassay because few antisera were specific for pancreatic glucagon. 
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ABSTRACT 
Twenty cows were assigned at parturition into two groups to study metabolic effects 
of continuous infusions of glucagon. Groups were normal controls and normal cows treated 
with glucagon at 10 mg/d for 14 d starting at 21 d postpartum. Daily blood samples and nine 
periodic liver biopsies were tziken from d 7 to d 49 postpartum. Plasma glucagon increased 
6- to 7-fold during infusions into treated cows. Plasma insulin increased during 
wk 1 of glucagon infusions. Plasma glucose increased by 11.5 and 9.0 mg/dl during wk I 
and wk 2 of glucagon infusions. Neither plasma NEFA. BHBA. nor urea N were affected by 
glucagon infusions. Liver glycogen decreased by d 2 of glucagon infusions, but it was 
restored by d 7 of infusions and had increased to 169% of the preinfusion baseline at 3 d after 
cessation of glucagon infusions. Milk production was less during glucagon infusions. Both 
milk protein yield and milk protein percentage decreased during glucagon infusions, which 
implies a decreased availability of amino acids for milk protein synthesis. Feed intakes did 
not increase during glucagon infusions, which was in contrast to the control group. The 
results indicate that glucagon infusions cause a net hepatic glycogenolysis initially and 
enhance plasma glucose concentrations, but there is no evidence for increased lipolysis from 
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adipose tissue. 
(Key words: dairy cows, glucagon, metabolism) 
Abbreviation key: BCS = body condition score. NC = normal control cows. NTG = normal 
cows treated with glucagon, TAG = triacylglycerols. 
INTRODUCTION 
Glucagon has broad metabolic effects on glucose, lipid, and amino acid metabolism 
both in vivo and in vitro as described in the literature. The major target organ of glucagon, 
however, is the liver where it stimulates both glycogenolysis and gluconeogenesis. thereby 
increasing hepatic glucose output (11. 12). Glucagon antagonizes actions of insulin in the 
liver and plays a major role, together with insulin, in regulation of glucose homeostasis for 
several physiological and nutritional conditions in nonruminants (26). By using various 
infusion techniques, such as a somatostatin clamp, the physiological actions of glucagon in 
vivo have been studied extensively both in humans and in dogs (11. 12. 20). 
Ruminants are in a continuous state of gluconeogenesis even whey they are in they 
fed state, which differs greatly firom nonruminants (2). The mechanisms for dietary and 
hormonal controls of glucose metabolism in ruminants are not thoroughly clarified; however, 
some studies have shown that hormones such as glucagon, insulin, growth hormone, 
glucocorticoids, and catecholamines play important roles in regulating glucose metabolism 
(23,24, 31). In sheep, short-term administration of glucagon increased the output of hepatic 
glucose and caused hyperglycemia, which were both exaggerated in insulin-controlled, 
alloxan-diabetic sheep (3. 7). Infusion of glucagon increased plasma glycerol when 
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glucagon-stimulated insulin release was prevented, an effect implying that glucagon 
increases lipolysis (7). In normal sheep, however, hyperinsulinemia prevented this increase, 
and concentrations of plasma NEFA actually decreased during infusions of glucagon (2). 
Further, glucagon showed no lipolytic effects in vitro in studies of adipose tissue from sheep 
and dairy steers (19). Therefore, the presence of a lipolytic effect of glucagon is still 
questionable in ruminants. 
In dairy cows, ketosis is a major metabolic disease that is characterized by 
hypoglycemia, depletion of liver glycogen, hyperketonemia, and fatty liver. Fatty liver 
seems to precede the occurrence of clinical ketosis. and ratios of liver triacylglycerols (TAG) 
to glycogen greater than 2.5 seem to be required for clinical ketosis to occur (17). Ketosis 
also is thought to generally result from inadequate availability of endogenous glucose (1). 
Our hypothesis was that exogenous glucagon infused into dairy cows would increased the 
availability of endogenous glucose without also increasing the availability of endogenous 
NEFA mobilized from adipose tissue. That hypothesis is part of a broader hypothesis that 
pharmacological infusions of glucagon would decrease development of fatty liver and 
clinical ketosis in lactating diary cows by increasing availability of glucose and increasing 
the ability of the liver to resist excess deposition of TAG. Therefore, our objective was to 
determine some of the pharmacological effects of long-term intravenous infusions of 
glucagon in normal, early-lactating dairy cows with an emphasis on metabolic regulation of 
glucose metabolism in a global manner. 
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MATERIALS AND METHODS 
Experimental Design, Treatment, and Management of Cows 
Twenty normal multiparous Holstein cows with an average body condition score 
(BSC) of approximately 3.6 at 15 d prepartiim were used. Cows were selected on the basis 
of having a ratio of liver TAG to glycogen (wt/wt) of less than 1.5 at 6 DIM. Pairs of cows 
calving in the same 2-wk interval were considered a block and randomly assigned to a group 
of either normal control (NC) cows infused with 0.15M NaCI or a group of normal cows 
treated with glucagon (NTG). This design provided 10 blocks or replications of the two 
treatments. 
For NTG cows, a subcutaneous polyethylene catheter was implanted into each jugular 
vein at 20 DIM. one day before infusions of glucagon were to begin. A catheter was 
implanted into only one jugular vein for NC cows. Lyophilized bovine glucagon (provided 
by Dr. Ronald Chance, Eli Lilly & Co.. Indianapolis. IN) was dissolved in 0.15 M NaCl at 
pH 10.25 with a final concentration of 20.833 ^g/ml. All glassware, pipettes, infusate 
containers, and infusion tubing in contact with glucagon solutions were rinsed before use 
with a 1% solution of enzyme-free BSA. Quantitative infusions into the NTG group and NC 
group were done continuously firom 21 to 35 DIM at a rate of 20 ml/h of either glucagon (10 
mg/d) or 0.15 M NaCl, respectively, via one catheter by using volumetric pumps (INFU-
CHECK™ model 1500, IVAC* Corporation, San Diego. CA). At the end of each 14-d 
infusion, the infusion rate was decreased by 2 ml/h every hour from 10:00 to 19:00 h to avoid 
abrupt withdrawal of glucagon. 
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All COWS were fed a TMR and grass hay during the prepartum period. The TMR (DM 
basis) consisted of 41% com silage, 15.4% alfalfa hay. 10.3% com gluten feed. 10.3% oat 
silage, and 23% concentrate containing 72% rolled com, 24% soybean meal, 1.1% Na,CO,. 
1.1% (Ca)3(P04),, 0.6% MgO, 0.6% NaCl, 0.3% CaCOj, and 0.3% X-Cel Ruminant Trace 
Mineral Premix ®. After calving, cows were fed ad libitum with 70% TMR. 5% whole 
cottonseeds, and 25% commercial supplement that contained 58% soy hulls. 24% soyPLUS. 
6.8% fish meal, 6.8% white grease, and 3.8% minerals. Diets were balanced according to 
NRC recommendations. Daily feed intakes were measured for each cow from 7 to 49 DIM. 
Three evaluators determined BSC at -30, -15. 1, 14. 34, and 49 DIM (18). Cows were 
housed in a tie-stall bam, milked three times daily, and weighed weekly from 1 to 49 DIM. 
Milk production was recorded daily. Milk samples were collected at 13. 20. 23. 34. 37. and 
49 DIM and analyzed for percentages of fat, protein, and lactose by mid-infrared 
spectrophotometry (Milk-O-Scan 203. Foss Food Technology. Eden Prairie. MN). All cows 
were handled and treated in accordance with guidelines established by the Iowa State 
University Animal Care Committee. 
Sampling Procedures 
Puncture biopsies of 4 to 6 g of liver were obtained under local anesthesia from each 
cow on 6, 13, 20, 23, 27. 35, 38.42, and 49 DIM. Most biopsies were done in the aftemoon 
except the biopsies on d 35, which were done at 21:00 h, 2 h after complete cessation of 
inftisions. Location of the liver was verified by ultrasound visualization. After a liver 
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sample was removed from the biopsy cannula, it was immediately placed on absorbent paper, 
blotted free of blood, frozen in liquid nitrogen, and stored at -80°C. 
Blood samples were withdrawn daily from the coccygeal vein from 7 to 49 DIM into 
vacuum mbes containing Na4-EDTA. Blood samples were collected before liver biopsies on 
days that biopsies were obtained. On the day an infusion was begim and on the day it was 
stopped, a series of blood samples were collected from the jugular catheter at short intervals. 
Blood samples were placed in ice until centrifiigation. which was done within 2 h after 
samples were withdrawn. Plasma was divided into three aliquots and stored at -20°C. One 
ml of plasma to be used for glucagon determinations was mixed with 500 KJU of aprotinin. 
an inhibitor of proteolysis (Boehringer-Mannhein, Cat. No. 1583794). before freezing. 
Analytical Procedures 
Frozen liver was powdered in liquid and homogenized in 7% perchloric acid 
(wt/vol); then, concentrations of glycogen were determined by an iodine binding assay (16). 
Lipid was extracted from powdered liver with 2:1 (vol/vol) chloroform-methanol, and 
concentrations of total lipid were determined gravimetrically after drying under a stream of 
air (17), which was determined to be equivalent to drying under N,. The lipid extract was 
redissolved in 3:2 (vol/vol) hexaneiisopropanol, and concentrations of TAG were determined 
(17). The DM percentages of liver samples were determined gravimetrically by weighing 
before and after lyophilization. Concentrations of plasma glucagon and insulin were 
determined by radioimmunoassay by using commercial kits (Diagnostic Products 
Corporation. Los Angeles, CA). Plasma metabolites (glucose, NEFA. BHBA. urea nitrogen) 
i 
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were determined by using a microcentrifugal autoanalyzer (Monarch Plus. Instrumentation 
Laboratory, Lexington. MA) and coupled enzymatic assays. 
Statistical Analysis 
The experiment was analyzed as a completely randomized block design. Data from 
the two treatment groups were subjected to ANOVA by using general linear models 
procedures of SAS (28). A separate analysis was done for each time period or sampling day 
to determine whether mean values for NC and NTG cows differed. Because of a few missing 
values, means were adjusted for block differences (LSMeans in SAS's Proc GLM). 
Additional analyses of time x treatment effects were done on functions of the repeated 
measures on the same cow, such as the differences between wk 3 and wk 4 or between wk 3 
and wk 5 in NC and NTG cows. The changes by time within each treatment group was 
evaluated by a paired / test (29) by testing whether differences between two times differed 
from zero when averaged over 10 cows. Tests of significance with P < 0.05 were considered 
statistically significant. 
RESULTS 
Plasma Hormones and Metabolites 
Plasma glucagon concentrations in NTG cows increased immediately after glucagon 
infusions began and plateaued during the entire infusion period, however, concentrations 
declined slightly from the beginning to the end (Figure 1 A). Overall, glucagon 
concentrations were elevated by 6- to 7- fold during glucagon infusions when compared with 
Figure 1. Concentrations of plasma glucagon and insulin in normal control cows (o) and 
normal cows treated with glucagon (•) from 21 to 35 DIM. Hormone 
concentrations shown in the figure are average values of two samples from two 
consecutive days around each biopsy, except values at the end of infusions were 
from samples 2 h after infusions. Values at the day infusions began and one day 
before infusions ended were from samples of only that day. Significant differences 
between treatments at a given time were indicated by *P<0.05, or ***/'< 
0.0001. A) Plasma glucagon; Time x treatment effects between d 20 and d 23. P < 
0.0001; d 20 and d 27, P < 0.0004; and, d 20 and d 35, P < 0.14. B) Plasma 
insulin: Time x treatment effects between d 20 and d 23, or d 35, P > 0 05; and, d 
20 and d 27, P < 0.02. 
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the preinfiision baseline. Plasma glucagon concentrations in NTG cows decreased 
immediately to slightly greater than that of NC cows after glucagon infusion ended, and the\ 
were less at d 7 than at d 49 postpartum in the NC group {P < 0.01). 
Plasma insulin concentration was significantly greater at d 7 of infusions of glucagon 
in the NTG group than in the NC group (Figure IB). Further, the time x treatment effect 
between d 20 and d 27 was significant (P < 0.02). Insulin concentrations of NTG cows 
decreased to that of NC cows at the end of glucagon infusions and increased thereafter. 
Thus, plasma insulin was increased by glucagon infusions; however, there were considerable 
variations in insulin values among individual cows as indicated by large values of SEM. One 
reason for the variations was the heterogeneous insulin responses of cows to glucagon 
infusions. Even in the first hours of glucagon infusions among the 10 NTG cows, six cows 
showed different degrees of increased plasma insulin, three cows did not change at all. and 
one cow had a doubtful response (data not shown). Plasma insulin concentrations were also 
less at d 7 than at d 49 postpartum in the NC group (P < 0.01). 
Weekly averages of plasma glucose concentrations in NTG cows (Figure 2A) 
increased by 11.5 (22%) and 9.0 mg/dl (17%). respectively, during the two weeks of 
glucagon infusions (i.e., wk 4 and 5) when compared with wk 3 before infiisions {P < 
0.0001). Plasma glucose of NTG cows in the first hours of glucagon infusion increased by 
14.4 mg/dl (27%) compared with the preinfiision baseline. It peaked 20 min after glucagon 
infusion began and plateaued for the remaining 3.67 h of sampling (data not shown). 
Concentrations of plasma glucose were elevated constantly throughout the glucagon infusion 
period in NTG cows. Glucose did not change in NC cows during wk 4 and 5. but it was 
Figure 2. Average concentrations of plasma metabolites ^ week in normal control cows 
(j ) and normal cows treated with glucagon (|) from 21 to 35 DEM. Significant 
d i f l f e r e n c e s  b e t w e e n  t r e a t m e n t  a t  a  g i v e n  t i m e  a r e  i n d i c a t e d  h y * P <  0 . 0 5 .  * *  p  <  
0.01, or *** P <0.001. A) Plasma glucose: Time x treatment effects between wk 
3 and wk 4, P < 0.004; wk 3 and wk 5, P < 0.0006; wk 3 and wk 6. P < 0.88; and, 
wk 5 and 6, P < 0.003. B) Plasma nonesterified fatt\'acids (NEFA). C) Plasma B-
hydroxybutyrate (BHBA). D) Plasma urea nitrogen; Time x treatment effects for 
NEF A, BHBA, and plasma urea nitrogen between wk 3 and wk 4, or wk 5, or wk 
6, and, wk 5 and 6 were P > 0.05. 
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greater in wk 7 than in wk 2 (P < 0.05). 
Plasma NEFA concentration (Figure 2B) decreased continually with lactation in both 
groups from wk 2 to wk 7, and, overall, it was less in NTG than in NC cows. The lower 
concentration of plasma NEFA was not caused by glucagon because it existed before 
infusions began, and time x treatment effects between preinfusion and during infusion were 
not present (P > 0.05). Therefore, plasma NEFA was influenced by stage of lactation but not 
by glucagon infusions. 
Neither plasma BHBA nor urea nitrogen were different between groups (Figure 2C 
and 2D) and. therefore, they were not affected by glucagon infusions. Also, their 
concentrations were relatively constant throughout the experiment. 
Composition of tlie Liver 
Liver glycogen contents in NTG cows were changed markedly by glucagon infusions 
(Figure 3A). When compared with 20 DIM as a baseline, liver glycogen concentration had 
decreased by an actual value of 0.94 ± 0.12% (P < 0.0001) at d 2 of glucagon infusions, but it 
was completely restored to baseline at d 7. Later, it increased to 1.32 ± 0.30% (P < 0.002) 
above baseline at d 14 of glucagon infusions and increased further to 1.65 ± 0.31% (P < 
0.0005) above baseline at 3 d after infusions ended. In contrast, there were no significant 
changes of liver glycogen in NC cows at any time. 
Liver TAG concentrations decreased significandy with the progression of lactation in 
both NC and NTG cows (Figure 3B). For instance, TAG decreased by actual values of 2.5 ± 
0.63% in NC cows (P < 0.004) and 3.0 ± 0.76% in NTG cows (P < 0.003) firom 7 to 49 DIM 
Figure 3. Composition of liver in normal control cows (o) and normal cows treated with 
glucagon (•) from 21 to 35 DIM. Significant differences between treatments at a 
given time were indicated by * P < 0.05 or** P < 0.01. A) Glycogen: Time x 
treatment effects between d 20 and d 23: P <0.03; d 20 and d 27, P < 0.21; d 20 
and d35, P < 0.03; and, d 20 and d 38, P < 0.003. B) Triacylglycerols Time • 
treatment effects between d 20 and other time: P > 0.05 
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(when results were compared on the basis of paired t test). Liver TAG did not differ between 
NC and NTG cows at any time (P > 0.05), and glucagon did not significantly affect liver 
TAG. 
The pattern of change for total liver lipids was similar to that of TAG in both groups 
(data not shown). Glucagon infusions did not affect total liver lipids. Overall average 
concentrations of total lipids were approximately 2% greater than those of liver TAG. which 
would be largely accounted for by structural phospholipids. Liver DM percentage did not 
change significantly over time in these normal cows; however, it was greater by 3.9% (P < 
0.05) and 4.6% (P < 0. 03) in NC cows than in NTG cows at 23 and 28 DIM, respectively. 
Milk Production and Composition 
Average daily milk production of NTG cows was significantly less than that of NC 
cows at wk 5 postpartum, which was the second week of glucagon infusions (Figure 4). 
When compared with wk 3, average daily milk production of NTG cows decreased by 2.6 ± 
0.9 (P < 0.02) and 3.0 ± 0.9 (P < 0.009) kg at wk 4 and wk 5 respectively, whereas milk 
production ofNC cows increased by 2.2 ± 1.4 (P < 0.16) and 3.7 ±2.1 (P < 0.02) kg at those 
times. During the first week after glucagon infusions ended, milk production in the NTG 
group increased by 3.3 ± 0.6 (P < 0.0003) kg, (i.e. wk 6 compared to wk 5). Therefore, daily 
milk production was decreased only transiently by glucagon infusions. 
Milk protein percentages (Figure 5A) had decreased by actual values of 0.47 ± 0.05% 
(P < 0.0001) at d 2 and by 0.22 ± 0.07% (P < 0.01) at d 13 of glucagon infusions when 
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Time postpartum (wk) 
Figure 4. Average daily milk production by week in normal control cows (S ) and normal 
cows treated with glucagon (|) from 21 to 35 DIM. Significant aifferences 
between treatments at a given time are indicated hy*P< 0.05. Time x treatment 
effects between wk 3 and wk 4. P < 0.002; wk 3 and wk 5. P <0.0005; wk 3 and 
wk 6. P < 0.05; and. wk 5 and wk 6. P < 0.05. 
compared with the preinflision baseline at 20 DIM. Two days after glucagon infusions 
ended, milk protein percentages had increased by 0.28 ± 0.07% (P < 0.003) when compared 
with d 13 of glucagon infusions. There were no significant changes in milk protein 
percentages in NC cows. Because both milk production and milk protein percentage 
decreased, average daily milk protein yield in NTG cows deceased to 76% and 78% of that in 
NC cows at d 2 and d 13 of glucagon infusions (data not shown). Obviously, milk protein 
synthesis was decreased significantly, but only temporarily by glucagon infusions. Although 
Figure 5. Percentages of protein, fat, and lactose in milk in normal control cows (o) and 
normal cows treated with glucagon (•) from 21 to 35 DIM. Significant differences 
between treatments at a given time are indicated by * P < 0.05, ** P < 0.01, or *** 
P< 0.001. A) Milk protein percentage; Time x treatment effects between d 20 
and d 23, P < 0.001; d 20 and d 34, P < 0.24; and, d 34 and d37, P < 0 GO 1 B) 
Milk fat percentage; Time x treatment effects between d 20 and d 23, or d 34. and. 
d 34 and d 37, P > 0.05. C) Milk lactose percentage. Time x treatment effects 
between d 20 and d 23, P < 0.001; d 20 and d 34, and, d 34 and dhl. P > 0 05 
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milk fat percentages were significeintly less at 34 and 49 DIM in NTG cows than in NC cows 
(Figxire 5B), glucagon infusions did not ziffect milk fat percentages because of nonsignificant 
time X treatment interactions (P > 0.05). In addition, there were no significant changes in 
milk fat percentages within both the NTG and NC groups before, during, and after infusions. 
Milk lactose percentage increased in actual values by 0.12 ± 0.03% at d 2 of glucagon 
infiisions when compzired with the preinfusion baseline of 20 DIM in NTG cows {P < 0.005). 
Also, milk lactose percentage at d 2 of glucagon infusions (Figure 5C) was greater in NTG 
cows than in NC cows (P < 0.007). Average daily yield of milk lactose, however, was not 
significantly affected by glucagon infiisions (P > 0.05. data not shown). 
Despite temporal changes in milk production and composition during infusions of 
glucagon. 305-d mature equivalents of milk, milk fat. and milk protein production per 
lactation between NTG and NC cows were not affected by glucagon infusions. Neither did 
305-d mature equivalents of milk, milk fat, and milk protein production differ between the 
current and the previous lactation in both the NTG and NC groups (data not shown). 
Feed Intake and BCS 
Average daily feed intakes in NTG cows were significantly less than intakes in NC 
cows during glucagon infiisions (Figure 6), but time x treatment effects were not significant 
(P > 0.05). Feed intakes for NC cows increased gradually after calving with a difference of 
4.62 ± 1.38 kg between wk 3 and wk 5 (P < 0.008). whereas feed intakes for NTG cows 
increased only 1.12 ± 1.25 kg firom wk 3 to wk 5 (P < 0.40). Feed intakes for NTG cows 
increased rapidly by 3. 06 ± 1.25 kg at wk 6 after glucagon infiision ended when compared 
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2 3 4 5 6 
Time postpartum (wk) 
Figure 6. Average daily feed intake by week in normal control cow (J ) and normal cows 
treated with glucagon (| ) from 21 to 35 DIM. Significant differences between 
treatments at a given time are indicated by * P < 0.05 or** P < 0.01. Time x 
treatment effects between wk 3 and wk 4. or wk 5, or wk 6. Z' > 0.05: wk 5 and wk 
6, P <0.01. 
with wk 5 C/' < 0.04). Thus, glucagon infusions hindered the normal increases of feed intakes 
with the progression of lactation as seen in NC cows. Although BCS were slightly lower in 
NTG cows at 14 and 35 DIM. BCS did not differ between NC and NTG groups at any time 
(data not shown). 
i 
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DISCUSSION 
This report presents results from the first known long-term administration of glucagon 
to lactating dairy cows. Normal cows were used to provide background information for 
further studies involving the use of glucagon to alleviate fatty liver in early lactation cows. 
The metabolic effects of glucagon infiosions into early-lactation dairy cows were evaluated by 
measuring changes of liver components, plasma metabolites and hormones, milk composition 
and yield, and feed intake before, during, and after glucagon. Intravenous administration of 
glucagon for 14 d did not show major detrimental effects that would indicate that glucagon 
could not be used for preventative or therapeutic purposes in high-producing cows. There 
were some short-term effects related to production performance, however, that are mildly, but 
not seriously, counterproductive. Such effects include: first, a temporary delay of the 
increase in feed intake that normally takes place in early lactation, second, a slight decrease 
in daily milk production, and third, a decrease in the concentration and yield of milk protein 
during the 2 wk when glucagon was infused. 
Most importantly, there were major improvements in both the carbohydrate and lipid 
status of these high-producing, early-lactation cows. Concentrations of blood glucose were 
increased significantly and immediately when infusions of glucagon began and remained 
increased throughout the infusions, indicating that glucose utilization is less than glucose 
production. The major utilization of glucose in lactating dairy cows is for milk production, 
which may account for up to 80% of total glucose utilization depending on the level of milk 
production (14). Glucose is used mainly for synthesis of milk lactose. Because the total 
daily lactose production was not changed and average daily milk production was decreased 
J 
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slightly by glucagon infusions, glucose utilization for milk production may have decreased 
slightly. Glucose utilization by muscle and adipose tissue, however, may have been 
increased slightly by increased plasma insulin and glucose during infusions of glucagon. 
Therefore, overall glucose utilization at least would not decrease during glucagon infusions. 
Also, glucose that was absorbed firom the gastrointestinal tract could not have been increased 
by glucagon because feed intakes did not increase during glucagon infusions as occurred in 
NC cows. Thus, increased plasma glucose probably results firom increased hepatic glucose 
production. Because liver glycogen concentrations in NTG cows were increased 
dramatically during the late part of glucagon infusions, despite initial decreases, hepatic 
gluconeogenesis most likely was increased by glucagon. 
Glucagon is known to increase gluconeogenesis both in vitro and in vivo (10. 11. 13). 
Glucagon infusions at high concentrations for a few hours increased the conversion of '''C-
alanine to '"'C-glucose in intact dogs, overnight fasted humans (10. 11), and sheep (6). 
Glucagon stimulates gluconeogenesis by affecting key regulatory enzymes found in 
hepatoc>tes and by increasing availability of gluconeogenic substrates in hepatocytes. A 
glucagon-induced, increased selective uptake of amino acids by the liver has been shown in 
many studies in nonruminants (4. 11, 20) and in ruminants (6, 9). If the supply of amino 
acids from extrahepatic tissues is not increased but the hepatic extraction of amino acids is 
increased, it follows that plasma amino acids should be decreased. A decrease in 
concentrations of plasma amino acids is a common feature during both hyperglucagonemia 
and exogenous glucagon infusions. Flakoll et al. (20) found that total plasma amino acids 
decreased by 17% in dogs when plasma glucagon was increased 4-fold while plasma insulin 
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was kept relatively unchanged. Moreover, a glucagon deficiency caused by somatostatin 
increased concentrations of plasma amino acids (5). Plasma amino acids were not measured 
in the present study, but decreases in both the percentage and yield of milk protein are 
consistent with decreased concentrations of plasma amino acids. This relationship occurs 
because milk protein synthesis is controlled by availability of plasma amino acids, and 
decreases in total plasma amino acids or a specific amino acid deficiency would severely 
impede milk protein synthesis. On the other hand, propionate is a major substrate for 
gluconeogenesis, but the effect of glucagon on utilization of propionate for gluconeogenesis 
is still uncertain. Glucagon stimulated hepatic uptake of propionate and gluconeogenesis in 
perfused sheep liver (25), but it did not affect in vivo utilization of propionate for glucose 
synthesis in sheep (8). It is unclear whether gluconeogenesis from propionate was increased 
by glucagon infusion in our current study. 
Liver glycogen decreased rapidly during the first 2 d after glucagon infusions began, 
which results fi-om glucagon-stimulated net glycogenolysis. The repletion of liver glycogen 
by d 7 of glucagon infiisions and its continued increase in the late part of infiisions and even 
3 d after infusions ended indicate a potent increase in glycogen synthesis in the liver of NTG 
cows. Glucagon stimulates glycogen phosphorylase very potently and induces 
glycogenolysis (30). However, the effect of glucagon on glycogen waned within 3 h of 
glucagon administration, even when counterregulatory insulin secretion did not occur in dogs 
fasted overnight (10). The reason for increases in glycogen after its initial depletion in our 
study is uncertain. In the first few hours after glucagon infiisions begun, increased plasma 
insulin probably counteracted glucagon to prevent fiorther net glucagon breakdown. 
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However, liver glycogen increased, while plasma insulin did not increase during the second 
week of glucagon infusions in NTG cows, hi addition, in another study with ketosis-
susceptible cows, the pattern of changes in liver glycogen was very similar to that of normal 
cows, but plasma insulin did not increase except for the first few hours during 14-d infusions 
of glucagon (unpublished data). Thus, factors other than insulin could regulate glycogen 
synthesis. It was hypothesized by Radziuk et al. (27) that metabolites, i.e.. gluconeogenic 
substrates, are the primary regulatory factors in glycogen synthesis. Although the 
mechanisms for this regulation are unidentified- they found that lactate stimulated glycogen 
synthesis during glucose loading (27). Because glucokinase activity is very low in ruminant 
liver (2), glycogen probably is synthesized primarily from gluconeogenic substrates. Our 
results suggest that this process could be stimulated by increased gluconeogenesis during 
glucagon infusion. 
The normal increase in feed intake usually seen in early lactation cows was decreased 
in magnitude by infusions of glucagon into NTG cows. Injections of glucagon decreased 
feed intake in rats, dogs, chickens, rabbits, and humans (21), and in sheep (15). Considering 
the major increases in plasma glucagon concentrations and the small inhibition of feed intake 
caused by glucagon infusions, it is likely that glucagon at physiological levels is not 
important in regulating feed intake. The reason for the decrease in daily milk production in 
NTG cows during glucagon infusions is unclear. The decrease may relate to feed intakes 
being limited by glucagon infusions in those cows. Milk production in dairy cows is affected 
by many factors, among which substrate supply and mammary blood flow are primary. 
Whether glucagon can directly affect the mammary gland is unclear because there is no 
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evidence of glucagon receptors in the mammary gland (22). The limitation in milk 
production is transient because milk production per lactation in NTG cows did not differ 
from that of NC cows or from the previous lactation. 
The most important observation with respect to lipids is that infusions of glucagon at 
10 mg/d did not give any indication of increasing lipolysis from adipose tissue and thereby of 
increasing concentrations of NEFA in blood. This is not the response expected based upon 
textbooks of physiology and biochemistry, which consistently indicated that glucagon is 
lipolytic with respect to adipose tissue. Average concentrations of NEFA were generally less 
in NTG than in NC cows, but these differences were present even before glucagon was 
infused. Plasma NEFA concentrations decreased during glucagon infusions in sheep (3) and 
in mid-lactation cows (unpublished data), which may be explained by increased 
concentrations of plasma insulin during glucagon infusions and by strong inhibitory effects 
of insulin on lipolysis. Thus, it is still unclear whether glucagon has any direct lipolytic 
effect in ruminants because concentrations of plasma insulin increased during glucagon 
infusions. Further studies are needed to clarify the effect of glucagon on lipolysis in 
ruminants. Concentrations of TAG in the liver decreased in NC and NTG cows with 
progression of lactation. Unfortunately, TAG percentages in livers of NTG cows were 
decreased even before inftisions of glucagon began, which prevented a decisive conclusion 
about whether glucagon causes an increased rate of removal of TAG from livers of normal 
dairy cows. Further studies are needed on this possible effect of glucagon, also. 
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CONCLUSIONS 
The main metabolic and performances changes caused by 14-d infiasions of glucagon 
at a pharmacological dose in normal early-lactation dairy cows in this study are: a) an initial 
net hepatic glycogenolysis followed by an increase in net glycogen synthesis, b) constant 
increases in plasma glucose during glucagon infusions, c) decreases in production of milk 
and milk protein, but no changes in milk lactose yield during glucagon infusions, d) a small 
inhibition of voluntary feed intake during glucagon infiisions, and e) increases in plasma 
insulin during the first week of glucagon infusions. Assuming that glucose utilization did not 
decrease during glucagon infusions, based on milk data and possible increases of glucose 
oxidization in muscles and adipose tissue by increased plasma insulin and glucose, the results 
suggest that glucagon in excess increases glucose production by increasing net 
glycogenolysis initially and then by promoting gluconeogenesis partly fi^om an increased 
hepatic uptake of plasma amino acids. The results of this study are not indication of a net 
lipolytic effect from glucagon infiisions in dairy cows. 
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REGULATION OF mRNA EXPRESSION FOR GLUCONEOGENIC ENZYMES 
DURING GLUCAGON INFUSIONS INTO LACTATING COWS 
A paper prepared for submission to the Journal of Dairy Science 
P. She, A. R. Hippen, G. L. Lindberg, D. C. Beitz, and J. W. Young 
ABSTRACT 
Effects of glucagon infusions on mRNA expression for gluconeogenic enzymes in 
lactating cows were studied. Normal and ketosis-susceptible cows were assigned into either 
glucagon-treated or control groups to give a 2 x 2 factorial design. Glucagon infusions at 10 
mg/d began at d 21 postpartum for 14 d. In normal cows, glucagon infusions increased 
plasma glucagon about 6-fold and increased plasma glucose 19%. Phosphoenolpyruvate 
carboxylase (PEPCK) mRNA decreased during wk 1 of glucagon infusions while plasma 
insulin increased. The susceptible cows had low plasma glucose and high BHBA before 
infusions. Glucagon infusions increased plasma glucagon about 8-fold and glucose 43%. but 
did not significantly change plasma insulin and hepatic PEPCK mRNA. PEPCK mRNA was 
greater overall in susceptible cows than in normal controls. In another experiment with mid-
lactation cows, 3.5-h glucagon infusions at 15 mg/d rapidly increased plasma glucose, insulin 
and decreased plasma BHBA and hepatic glycogen. PEPCK mRNA decreased 41%. but 
mRNA for pyruvate carboxylase increased 50% by the end of 3.5-h glucagon infusions, and 
mRNA for fhictose 1, 6 bisphosphatase was not influenced. We conclude that PEPCK gene 
expression in normal cows is inhibited potently by insulin to balance elevated carbohydrate 
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status during glucagon infusions. PEPCK mRNA expression probably is not involved in the 
pathogenesis of bovine ketosis. 
INTRODUCTION 
Concentrations of plasma glucose are maintained within narrow ranges in both 
ruminants and nonruminants to maintain normal body functions. In nonruminants. the liver 
regulates glucose homeostasis in many physiological and nutritional conditions through ke\ 
regulatory enzymes. These regulatory enzymes of glycogen metabolism, gluconeogenesis. 
and glycolysis are controlled acutely and chronically by hormones and nutrients. Metabolic 
fluxes of substrates through individual metabolic pathways are enhanced or inhibited 
accordingly (37). 
In dairy cows, ketosis is a common metabolic disorder associated with disturbances of 
both carbohydrate and lipid metabolism. Ketosis is characterized by hypoglycemia, 
depletion of liver glycogen, ketonemia, and fatty liver. The pathogenesis of ketosis is not 
known clearly; however, it is generally thought to result from inadequate availability of 
endogenous glucose (2). It is still questionable whether the gluconeogenic capacity of the 
liver of ketosis-susceptible cows is impaired, thereby causing ketosis (2. 35). An 
experimental model of ketogenesis in lactating dairy cows has been developed. This model, 
which was identified as feed restriction and butanediol feeding (FRBD), has been used to 
induces a metabolic state that resembles ketosis (34). 
Glucose metabolism in ruminants differs from that of nonruminants. First, because 
most dietary carbohydrate is fermented in the nunen and only small amounts of glucose are 
absorbed directly from the gastrointestinal tract, over 90% of the glucose supply of ruminants 
depends on a state of continuous gluconeogenesis. which increases after feeding (29. 31). 
Second, demands for glucose in lactating ruminants are great because a large proportion of 
available glucose is used for lactose synthesis during the whole period of milk production. 
Third, ruminants oxidize limited amounts of glucose and use acetate rather than glucose for 
fatty acid synthesis (4). As a result, plasma glucose concentrations are much lower in 
ruminants than in nonruminants. 
In general, gluconeogenic rate is controlled by substrate availability, quantities of 
rate-limiting enzymes, and the state of activation of rate-limiting enzymes, all of which are 
influenced by hormones. The availability of gluconeogenic substrates is a major determinant 
for the rate of gluconeogenesis in ruminants (31). The mechanisms of hormonal control of 
gluconeogenesis and its enzymes have not been studied intensely in ruminants; however, 
hormones such as glucagon, insulin, growth hormone, glucocorticoids, and catecholamines 
play important roles in regulating glucose metabolism (6. 33). Comparative studies in 
ruminants and nonruminants of lactation, ketosis. fasting, or hormonal treatments have 
shown that gluconeogenic enzyme activities from ruminant liver were sometimes 
inconsistent and differed from those in nonruminants (3. 4, 5, 19). For example. PEPCK (EC 
4.1.1.32) adapted little to changes in physiological or nutritional conditions (4. 47). 
Regulatory differences may exist among species because nutrition and endocrine status varies 
widely among species. Metabolic regulation at the molecular level can be understood by 
using new molecular technology to smdy physiological conditions in animals and cells (21). 
In nonruminants. extensive studies have been made of nutritional and hormonal regulation of 
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gene expression for some enzymes of glucose metabolism both in vivo and in vitro (25. 37). 
but very few studies of this kind have been done with ruminants. 
Ruminants are highly dependent on gluconeogenic pathways for regulation of blood 
glucose. Glucose-6-phosphatase (EC 3.1.3.9), &uctose-1.6-bisphosphatase (FBPase, EC 
3.1.3.11), pyruvate carboxylase (EC 6.4.1.1). and PEPCK are the four key regulatory 
enzymes of gluconeogenesis. We hypothesize that hormonal regiilation of gene expression 
for these gluconeogenic enzymes is critical in controlling glucose homeostasis in response to 
hormonal status, as well as in development of ketosis in dairy cows. The first goal of this 
study was to determine whether several metabolic variables and gene expression of selected 
gluconeogenic enzymes were influenced by infusions of glucagon into normal lactating dair\ 
cows. Also, we induced ketosis by using the FRBD protocol to approach the second goal, 
which was to determine whether expression of the PEPCK gene is involved in the 
pathogenesis of ketosis and the response of ketosis-susceptible dairy cows to glucagon 
infusions. Accomplishing these two goals will contribute to greater understanding of 
carbohydrate regulation in normal cows and to understanding the molecular pathogenesis of 
ketosis. 
MATERIALS AND METHODS 
Long-term Infusions of Glucagon into Dairy Cows 
The objective was to determine chronic changes of PEPCK mRNA and its metabolic 
relationships by modifying hormonal and nutritional conditions in dairy cows. Twenty 
normal multiparous Holstein cows with an average body condition score of approximately 
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3.6. and 20 obese multiparous Holstein cows with body condition scores over 4 on a scale of 
1 to 5 at d 15 prepartum were used. Normal cows and obese cows (cows that were 
susceptible to ketosis) were selected on the basis of having ratios of liver triacylglycerols to 
glycogen (wt/wt) of less than 1.5 and greater than 2.5 at 6 DIM, respectively. Four (two 
normal and two susceptible) cows calving in the same 2-wk interval were considered a block. 
The two normal cows were assigned randomly to two groups identified as normal controls 
(NC) or normal cows treated with glucagon (NTG). The two susceptible cows were assigned 
randomly as susceptible controls (SC) or susceptible cows treated with glucagon (STG). 
TTius. there were 10 blocks or replications of a 2 x 2 factorial design with two nutritional 
backgrounds (normal and obese) and two levels of glucagon (0 and 10 mg/d). 
Normal cows were fed a TMR and grass hay according to NRG reecommendations 
during the prepartum period. Susceptible cows were made obese by feeding extra com at 5.5 
kg/d during the last 30 d prepartum. The general layout of the experiment is shown in Figure 
1. Both groups of susceptible cows received FRBD from 14 to 42 DIM to induce ketosis. 
During FRBD, the susceptible cows were feed-restricted to about 80% of the maximum 
intake determined during the two consecutive days just before FRBD. Also, a ketone body 
precursor, 1.3-butanediol, was added to the diet. Except for FRBD, treatment and 
management of susceptible cows after calving was the same as for normal cows. From 21 to 
35 DIM, both NTG and STG cows were infused continuously through one jugular vein with 
glucagon (10 mg/d), while both NC and SC cows were infused with 0.15 M NaCl (20 ml/h). 
Nine liver biopsies (days identified in Figure 1) and daily blood samples were obtained 
during the 42 d experimental period from 7 to 49 DIM. Details of catheterization, infusion 
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Figure I. Experimental protocol for long-term infusions of glucagon. Four groups of cows as 
described in "Materials and Methods" were used in the experiment began from 7 to 
49 DIM. Only the susceptible cows received feed restriction and butanediol 
(FRBD) from 14 to 42 DIM. Glucagon was infused intravenously into each group 
of normal and susceptible cows from 21 to 35 DIM. LB stand for liver biopsy. 
conditions, liver biopsy and other sampling procedures, and feeding were described 
elsewhere (43). 
Short-term Infusions of Glucagon into Dairy Cows 
The objective was to determine acute effects of glucagon infusions into normal dairy 
cows on the regulation and time course of PEPCK mRNA and other metabolic parameters. 
Two days before infusions, polyethylene catheters were implanted into each jugular vein. 
Five mid-lactation Holstein cows were infiised continuously via one catheter with glucagon 
for 3.5 h at 15 ng/(kgxmin). Four weeks later, they were infused with 0.15 M NaCl (20 ml/h) 
to give control values. The dosage of glucagon (15 mg/d) was 1.5 fold greater than for the 
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long-term study. Five liver biopsies were obtained for each infusion (at 0. 0.75. and 3.5 h 
during infusions, and at 2 h and 3.5 h postinfusion). Each liver sample weighed about one 
gram. A series of blood samples was collected pre, during, and postinfusion firom the other 
catheter. Sampling was begun at about 8 a.m., just after feeding and milking, and ended at 
about 2 p.m. Feed and water were available to the cows during the experimental period. 
RNA Isolation and Northern Blotting 
Frozen liver samples stored at -80 °C were powdered by grinding in liquid N. and 
total RNA was extracted from about 100 mg of tissue by using TRJzoF" Reagent (Life 
Technologies. Inc.. Grand Island, NY). Total RNA was quantified spectrophotometrically at 
260 nm and stored at -80 °C. Ratios of absorbencies at 260 nm to 280 nm were calculated to 
determine the quality of RNA isolated. RNA isolation and analyses were done as soon as 
possible to avoid degradation of mRNA. 
Twenty jig of total RNA was electrophoresed through 1% agarose gels containing 
formaldehyde. The gels were stained with ethidium bromide and, upon exposure to 
ultraviolet light, the 18S and 28S rRNA could be seen intact and were of similar size across 
samples. Nucleic acids were transferred to nylon membranes (Magnacharge. MSI. Westboro, 
MA), and membranes were prehybridized. hybridized, washed, and exposed to x-ray films 
for 1 to 5 days according to the intensity of radioactivity (40). An about 2 kb cDNA clone 
for human PC gene encoding the 3' end (provided by B. H. Robinson, Hospital for Sick 
Children, Toronto, Ontario) was used first. Then, the membrane was stripped and hybridized 
with FBPase probe made from a pig cDNA clone of about 1 kb in length, which was 
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subcloned into Pet-1 la with BamHl dmAXba (provided by H. J. Fromm, Iowa State 
University, Ames, lA). Finally, they were hybridized with a probe made from a 2.1 kb insert 
from the Hind III site of the chicken P-actin cDNA. Probes for these cDNA clones were 
made by the random primer method using [a-"P]-dCTP (300 Ci/mmol) (RadPrime DNA 
labeling System, Life Technologies, Inc.. Grand Island, NY). The densities of bands were 
determined by image densitometric analysis at the Iowa State University Image Analysis 
Facility. Concentrations of P-actin mRNA were used to correct for loaded amoimts of total 
RNA samples, and relative concentrations of PC mRNA and FBPase mRNA were calculated. 
Solution Hybridization 
Two subclones for rat PEPCK cDNA. PCK.Ll 1 and PCK.L15 were derived from a 
full-length PEPCK cDNA clone, PCKIO (provided by Dr. R. W. Hanson, Case Western 
University. Cleveland, OH). The inserts were subcloned in pBluescript KS+, and their 
sequences were verified so that they could be used as templates for making riboprobe and 
single strand DNA (ssDNA) for standards in solution hybridization, respectively. An 
antisense RNA riboprobe containing 417 bp of the PEPCK gene was synthesized by using T3 
RNA polymerase and an in vitro transcription kit (MAXIscript™. Ambion. Austin. TX). A 
3.4 kb DNA fragment from digestion of PCK.Ll I with Sam I was used as a template. The 
antisense RNA was labeled with [^^S]-UTP (10 mCi/ml, specific activity > 1,000), and 
incorporation rates of radioactive UTP were greater than 50%. ssDNA. which was the sense 
strand of PEPCK gene, was synthesized by culture of bacteria containing PCK.Ll 5 and co-
infection with Ml3 helper phage. 
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A range of amounts of ssDNA and 5 |ig of total RNA for each sample were 
hybridized overnight with the riboprobes in solution at 72 °C. Double strand hybrids 
protected from RNase A and RNase TI were precipitated by trichloroacetic acid and captured 
by filtration under vacuum on Whatman GF/C glass filters. Radioactivity was counted by 
liquid scintillation spectroscopy, and the content of mRNA was calculated by using standard 
curves. The intra-assay and inter-assay CV were 2.8% and 9.8%. respectively, and the 
average r for the standard curves in a total of 24 assays was 0.997 (data not shown). 
Analytical Procedures 
The methods for analyzing liver glycogen and triacylglycerols, plasma metabolites 
(glucose, NEFA. and BHBA). and plasma hormones (glucagon and insulin) were described 
earlier (43). Plasma metabolites for the study of short-term glucagon infusions were 
determined manually. Plasma glucose was measured by the glucose oxidase method 
(Glucose Trinder. Sigma Diagnostic. St. Louis. MO). Plasma NEFA were analyzed by a 
commercial kit (NEFA-C. Wako Pure Chemical Industries. Ltd. Osaka, Japan). Plasma 
BHBA was measured according to Williamson, et al. (46). 
Statistical Analysis 
Data from both the long-term and the short-term studies of glucagon infusions were 
subjected to ANOVA by using the general linear models procedures of SAS. A separate 
analysis was done for each time period or sampling time point to determine whether mean 
values for two individual groups differed. The changes over time within each treatment 
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group were assessed by a paired t test (44) by testing whether differences between two 
selected times differed from zero. For the short-term study, additional analyses of time x 
treatment effects were done on functions of difference between the repeated measures on the 
same cow to test two differences for glucagon-treated and control cows. Associations 
between PEPCK mRNA and other metabolic parameters in the long-term study were 
calculated by Pearson correlation analysis. 
RESULTS 
Loag-term Infusions of Glucagon into Dairy Cows 
Plasma glucagon concentrations in NC cows increased from wk 2 to wk 7 (P < 0.02). 
and the average concentration was greater in NC cows than in SC cows (P < 0.06. Table 1). 
Plasma glucagon concentrations increased 6- to 7-fold in NTG cows and 8- to 9-fold in STG 
cows during glucagon infusions (Table 1). Plasma insulin concentrations of NC and SC 
cows increased from wk 2 to wk 7. but the average concentration was greater in NC cows 
than in SC cows {P < 0.0007. Table 1). Concentrations of plasma insulin were significantK-
greater during wk 1 of glucagon infusions in NTG cows than in NC cows {P < 0.05), but did 
not differ during wk 2 of infusions (P > 0.05). Plasma insulin concentrations did not differ 
between STG and SC cows at wk 1 and wk 2 of infusions {P < 0.02), however, plasma 
insulin in STG cows increased during the first 4 h of glucagon infusions (data not shown). 
Plasma glucose concentrations (Table 1) increased slightly from wk 2 to wk 7 in NC 
cows (P < 0.05). Glucose concentrations increased 19% (10.1 mg/ml) over preinfusion 
baseline during glucagon infusions in NTG cows (P < 0.0004) and 43% (17.3 mg/ml) in 
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Table 1. Weekly average concentrations of plasma glucagon, insulin, glucose and B-
hydroxybutyrate (BHBA) in normal controls (NC). normal cows treated with 
glucagon (NTG). susceptible controlc (SC), and susceptible cows treated with 
glucagon (STG). 
E'reinfiision infusion Postinfusion 
Variable Treatment' 
Week postpartum 
2 3 4 5 6 7 SEM-
Glucagon NC 72 85 91 94 104 114 13.S 
(pg/ml) NTG 74 89 597 501 128 112 24.8 
SC 56 63 75 68 59 55 4.0 
STG 78 65 668 568 119 96 9.4 
Insulin NC 302 405 349 364 447 495 28.3 
(pg/ml) NTG 315 415 664 477 547 519 58.2 
SC 209 209 229 266 253 340 16.6 
STG 252 248 257 331 278 357 30.6 
Glucose NC 50.0 51.9 51.0 51.9 54.5 54.7 1.2 
(mg/dl) NTG 52.5 52.7 64.0 61.6 55.5 55.3 1.0 
SC 46.4 41.6 36.7 37.6 43.3 53.5 2 '' 
STG 47.0 39.8 52.2 62.0 46.6 53.5 2.4 
BHBA NC 7.4 6.8 9.6 6.7 6.1 5.6 0.8 
(mg/dl) NTG 6.2 6.8 8.6 7.8 6.3 5.6 0.9 
SC 16.0 21.3 35.7 32.8 30.9 11.0 2.0 
STG 15.5 25.9 34.6 25.1 21.6 6.8 2.6 
' All four groups of cows were infused during week 3 and 4 postpartum either with 0.15 M 
NaCI (NC and SC) or glucagon (10 mg/d, NTG and STG). The SC and STG groups were 
subjected to the feed restriction and butanediol protocol from week 3 through week 6. 
" The general SEM of that group. Selective statistical conclusions are described in "Results". 
STG cows (P < 0.0001). Plasma glucose decreased at wk 3 compared with wk 2 in SC {P < 
0.04) and STG (P <0.002) cows, after FRBD feeding was begun. FRBD feeding to SC and 
STG cows ended at wk 6, and in wk 7 glucose concentrations increased in SC {P < 0.01) and 
STG {P < 0.01) cows (Table 1). Plasma BHBA concentrations (Table 1) were greater both in 
SC and STG cows before FRBD feeding was initiated {P < 0.006). and BHBA increased 
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during the FRBD feeding in SC and STG cows (P < 0.01). FRBD feeding has been shown 
previously to increase plasma ketone concentrations (Mills, 1986), and BHBA concentrations 
at 1 wk after FRBD decreased rapidly {P < 0.001). 
Concentrations of hepatic PEPCK mRNA (Figure 2) were similar for cows in all 
treatments at day 7 postpartum {P > 0.05). PEPCK mRNA was greater in SC cows that had 
undergone the FRBD dietary treatment beginning at d 14 postpartum, than in NC cows at d 
20 (? < 0.04), d 38 (/»< 0.01), and d 42 (Z' < 0.03) postpartum. PEPCK mRNA 
concentrations in NTG cows decreased during the first 7 d of glucagon infusions (P < 0.03). 
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Figure 2. Concentrations of PEPCK mRNA in normal controls (NC, o), normal cows treated 
with glucagon (NTG, •), susceptible controls (SC, •), and susceptible cows treated 
with glucagon (STG, •). The general SEM are 4.8 for NC cows, 3.7 for NTG 
cows, 7.6 for SC cows, and 5.3 for STG cows. Treatments of cows were described 
in "Materials and Methods"; and the statistical analysis was described in "Results". 
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but increased between d 7 and d 14 of glucagon infusions to near preinfusion levels (Figure 
1) at the same time that plasma insulin concentrations were decreasing (Table 1). In SC and 
STG cows, PEPCK mRNA concentrations seemed to decline during infusions, but did not 
differ significantly between groups during the entire experimental period {P > 0.05). 
Short-term Infusions of Glucagon into Normal Dairy Cows 
During the long-term infusions of glucagon, plasma glucagon and glucose were 
increased, whereas plasma insulin increased only during the first week of infusions into NTG 
cows (Table 1). Expression of the PEPCK gene, which was expected to increase during 
glucagon infusions on the basis of known responsiveness of the PEPCK gene to glucagon, 
instead declined during infusions (Figure 2). Therefore, short-term infusions of glucagon 
were conducted with frequent sampling of liver and blood to determine whether PEPCK gene 
expression was acutely responsive to glucagon. 
Plasma glucagon and insulin concentrations increased 8-fold (Figure 3A) and 3.8-fold 
(Figure 3B), respectively, during the first 2 h of glucagon infusions. Glucagon 
concentrations remained high tliroughout infusions, whereas insulin concentrations declined 
steadily beginning at 2 h of infusions and were still greater than baseline at the end of 
infiisions {P < 0.003, Figure 3B). At the completion of glucagon infiisions, plasma glucagon 
decreased rapidly to baseline concentrations, and plasma insulin decreased to below baseline 
concentrations {P < 0.03, Figure 3B). 
Liver glycogen concentrations decreased from 3.5% to 2.1% during the first 0.75 h of 
glucagon infusions (Figure 4A, time x treatment interaction P < 0.02) and decreased further 
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Figure 3. Concentrations of piasma glucagon and insulin in control (o) and glucagon-treated 
(•) cows. A) Glucagon: Time x treatment effects between pre-infiision and during 
infusion, P < 0.001; between pre-infusion and post-inflision, P < 0.28. B) Insulin; 
Timextreatment effects between pre-infiision and during infusion. P < 0.005: 
between pre-infiision and post-inflision, P < 0.03. 
Figure 4. Concentrations of liver glycogen and plasma metabolites in control (o) and 
glucagon-treated (•) cows. A) Liver glycogen: Time x treatment effects between 0 
and 0.75 h, P < 0.02; between 0 and 3.5 h, P < 0.02; between 0 and 5.5 h, P < 0 01. 
between 0 h and 7h;P<0.03. B) Plasma glucose: Time x treatment effects 
between pre-infusion and during infusion, P < 0.001; between pre-inflision and post-
infiision, P < 0.89. C) Plasma nonesterified fatty acids: Time x treatment effects 
between pre-infiision and during infusion, P < 0.31; between pre-infusion and post-
infusion, P < 0.25. D) Plasma P-hydroxybutyrate: Time x treatment effects 
between pre-infusion and during infusion, P < 0.36; between pre-infusion and post-
infusion, P < 0.89. 
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through the remainder of infusions. Liver glycogen of glucagon-treated cows did not 
increase during the 3.5 h postinfusion period. Plasma glucose concentrations increased 1.5-
fold during the first hour of glucagon infiisions (Figure 4B). At 2 h of glucagon infusions, 
insulin was still at its maximal concentration (Figure 3B), but plasma glucose concentration 
had declined from peak values (Figure 4B, P < 0.04). Plasma glucose concentrations were 
similar in preinfusion and postinfusion periods (P > 0.05). Plasma NEFA concentrations 
decreased by 115 ^eq/L during infusions (P < 0.03) and increased after infusions ended 
(Figure 4C). Plasma BHBA was not influenced by short-term infusions of glucagon (Figure 
4D). 
PEPCK (data not shown) and PC mRNA (Figure 5) were detected as single mRNA 
transcripts by Northern blotting, and corresponded to 2.8 kb and 4.2 kb. respectively, which 
agrees with rat mRNA sizes (14, 27). FBPase. however, was detected as a major transcript of 
1.4 kb that agrees with rat FBPase mRNA size (18) and a minor transcript of 2.1 kb. and both 
transcripts were integrated by scanning densitometry. 
Concentrations of hepatic PEPCK. mRNA as determined by solution hybridization 
tended to increase during the first 0.75 h of glucagon infusions (F < 0.1). but PEPCK mRNA 
concentrations at 3.5 h of glucagon infusions decreased to 59% of preinfusion baseline 
(Figure 6A, P < 0.03) and remained decreased through 2 h postinfusion. Interestingly. 
PEPCK mRNA concentrations at 3.5 h of infiisions increased 31% in control cows that were 
infused with 0.15M NaCl (P < 0.01) and remained increased at 2 h postinfusion. 
The abundance of PC mRNA as determined by Northern blotting and scanning 
densitometry increased 1.5-fold at the end of infusions (P < 0.006) and remained increased 
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Figure 5. Northern blotting of pyruvate carboxylase (PC) mRNA and fructose 1,6 
bisphosphatase (FBPase) mRNA in dairy cows in response to glucagon infusions. 
Treatments of cows were described in "Materials and Methods". Lanes 1, 2 and 3 
are 0,0.75 and 3.5 h of glucagon infusions, respectively. Lanes 4 and 5 are 2.0 and 
3.5 h post-infusion, respectively. 
Figure 6. Concentrations of mRNA for liver gluconeogenic enzymes in control ) and 
glucagon-treated (|) cows. A) Phosphoenolpyruvate carboxylase (PEPCK) 
mRNA; Time x treatment effects between 0 and 0.75 h, f < 0.20; between 0 and 
3.5 h, P < 0.01; between 0 and 5.5 h, P < 0.005; between 0 and 7 h, P < 0.10. B) 
Pyruvate carboxylase (PC) mRNA; Time x treatment effects between 0 and 3 .5 h; 
P < 0.21; between 0 and 5.5 h, P < 0.08; between 0 and 7 h, P < 0.27. C) Fmctose 
1, 6 bisphosphatase (FBPase) mRNA; Time x treatment effects between 0 and 3.5 
h, P < 0.26; between 0 and 5.5 h, P < 0.65; between 0 and 7 h, P < 0.98. 
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even at 3.5 h postinfusion (Figure 6B). However, the time x treatment effects were not 
significant, which was probably due to high variability. FBPase mRNA was unaffected b\ 
glucagon infusions (Figure 6C). 
DISCUSSION 
Regulation of mRNA for PEPCK, PC, and FBPase by Glucagon Infusions 
By performing multiple liver biopsies during glucagon infusions, we were able to 
study the temporal regulation of gene expression of some gluconeogenic enzymes in dair\-
cows. Infusions of glucagon in the short-term and long-term experiments caused a net 
decrease in hepatic expression of PEPCK mRNA. These decreases were especially apparent 
in the short-term study where abundance of PEPCK mRNA had decreased after 3.5 h of 
glucagon infiisions. The decrease in PEPCK mRNA expression by glucagon infusion is 
contrary to the known activation of PEPCK transcription by glucagon or cAMP (8. 14. 15. 
30), but is explained by the stimulation of endogenous insulin secretion during glucagon 
infusions. Insulin is a potent down-regulator of PEPCK transcription in vitro and in animals 
(14. 20, 23. 28, 41). When plasma insulin concentrations were greater, such as in the NTG 
cows during wk 1 of glucagon infusions, PEPCK mRNA declined and reached a nadir at d 35 
postpartum, near the time of maximal plasma insulin (43). During wk 2 of glucagon 
infusions, PEPCK mRNA increased while plasma insulin declined. Moreover, in SC and 
STG cows that were made susceptible to ketosis by accumulation of fat in the liver, plasma 
insulin concentrations increased little in response to glucagon infusions and PEPCK mRNA 
did not decrease as much as it decreased in normal cows. In the SC cows, plasma 
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concentrations of insulin and glucose were lower than those for any other treatment groups, 
and abundance of PEPCK mRNA was the greatest nearly throughout the experiment. On the 
basis of the inverse relationship between PEPCK mRNA and plasma insulin concentrations, 
we conclude that PEPCK mRNA expression was down-regulated by endogenous insulin 
during glucagon infusions. 
Many regulators affect PEPCK gene transcription, and effects of cAMP and insulin 
have been defined most clearly (25). In H4IIE hepatoma ceils, Granner et al. (23. 42) found 
that cAMP increased PEPCK gene transcription within 5 min. transcription was ma.Kimal 
within 30 min, and insulin at 5 nM decreased PEPCK transcription by 50% within 15 min. 
Insulin repression of PEPCK occurred both in untreated cells and in cells treated first with 8-
(4-chlorophorylthio)-cAMP, dexamethasone, or both. From this study and others, insulin is 
understood to play a dominant inhibitory role in the transcriptional regulation of PEPCK (22. 
23, 32, 41. 42). Plasma glucagon increased much greater than did insulin in the current 
study, but the dominant inhibitory role of insulin in vivo is nevertheless sufficient to override 
glucagon stimulation and suppress PEPCK transcription, in agreement with previous studies 
(22,23. 42). 
The PC transcript was expressed as a single transcript of 4.2 kb, which is similar to 
that of non-ruminant species (27). PC increased during the first three hours of glucagon 
infiisions, but molecular regulation of the PC gene is not as well understood as that for 
PEPCK. Because PC is a key gluconeogenic enzyme, we expected its transcriptional 
regulation to be similar to that of PEPCK. Like PEPCK, the amount of PC protein was 
increased by fasting and diabetes (39). The pattern of gene expression in the current study 
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may suggest glucagon or cAMP stimulation of PC mRNA expression with little repression 
by insulin, but further studies on hormonal regulation of PC gene are warranted. 
FBPase was detected as two transcripts, both of which were varied together. FBPase 
transcription in rats is activated by cAMP but. similar to PEPCK. is repressed by insulin (17. 
18). In the current study, FBPase mRNA abundance was not affected by glucagon infusions. 
FBPase mRNA has a half life of 6 h (18), whereas the infusion period lasted 3.5 h. The 
relatively long half-life of FBPase mRNA can explain the lack of FBPase repression in the 
current study, whereas abundance of PEPCK mRNA could be more sensitive to 
transcriptional down-regulation because the half-life of its mRNA is approximately 0.5 h 
(36). Alternatively, PC gene regulation could have a differently sensitivity to insulin and 
glucagon than does PEPCK. 
Effects of Glucagon Infusions on Glucose Metabolism in Normal Cows 
For the short-term glucagon infusions, cows were infused with 1.5-fold the dose of 
glucagon that was used in the long-term study. As a result, net increases in concentrations of 
plasma glucose and insulin were greater than those observed in the long-term smdy. Liver 
glycogen decreased 2.1% (actual value) over 3.5 h of glucagon infusions, but two-thirds of 
this decrease occurred within the first 0.75 h of glucagon infusions (Figure 4). This result 
confirms the initial glycogenolysis that was observed in our study of long-term glucagon 
infusions (43). By using isotopic techniques, Cherington et al. (12) also found that initial 
glycogenolysis in overnight fasted dogs occurred within 3 h of glucagon infusions, but waned 
with time even when increases in plasma insulin were prevented. Decreases in 
i p 
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concentrations of PEPCK mRNA by the end 3.5-h glucagon infusions may reflect a negative 
response to increases in plasma glucose concentrations caused by initial net glycogenolysis 
during glucagon infusions. 
Although gluconeogenic rates and hepatic glucose output were not determined 
directly by isotopic techniques in our studies, increased gluconeogenesis caused by long-term 
infusions of glucagon into normal cows was suggested indirectly (43). Liver glycogen 
decreased at d 2 of glucagon infusions and but was restored completely by d 7 of glucagon 
infusions. Plasma insulin increased during wk 1 of glucagon infusions and could have 
stimulated glucose oxidation in the peripheral tissues. Therefore, constant increases in 
plasma glucose must result from initial glycogenolysis and later gluconeogenesis during wk 1 
of glucagon infusions. Glucagon can stimulate gluconeogenesis by several means. First, 
glucagon increased hepatic uptake of plasma amino acids in dogs, humans (13). and sheep 
(10) Second, glucagon increased fatty acid oxidation in perfused liver and in isolated 
hepatocytes (16). thereby increasing cellular concentrations of acetyl-CoA to activate PC. 
Enzymatic activity of PC was increased by glucagon infusions in sheep (11); and our data 
also show that PC mRNA was increased by glucagon infusions. Actually, pyruvate 
carboxylation by isolated hepatocytes was increased by glucagon (1, 16. 38). All these 
factors can increase the availability of OAA, the substrate for PEPCK, in hepatocytes. which 
would increase the flux rate through PEPCK (25) and promote gluconeogenesis. Third, 
glucagon caused increased mitochondrial matrix volume, activated respiratory chain, and 
increasing pyruvate carboxylation. citrulline synthesis, and glutaminase activity in isolated 
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hepatocytes (24. 38). Stimulation of these mitochondrial processes could promote 
gluconeogenesis. 
In overnight fasted dogs, simultaneous 4-fold increases of glucagon and insulin for 3 
h caused significantly decreased glucose production and increased glucose utilization, and 
insulin was thought to be a potent inhibitor of the stimulatory effects of glucagon on 
glycogenolysis and gluconeogenesis (45). In sheep, insulin at physiological ranges inhibited 
gluconeogenesis (9). Our data suggest that PEPCK mRNA expression is inhibited in vivo b\-
insulin, even in the presence of high glucagon concentrations. PEPCK has no known 
allosteric effectors and is not regulated by covalent modification, and the main regulation was 
at the mRNA level (25). Thus, decreases in PEPCK mRNA may reflect sensitive hormonal 
regulation of the PEPCK gene to balance increases in net glycogenolysis and 
gluconeogenesis during glucagon infusions. 
Bassett (7) discussed the balance between the effects of insulin and counter-regulatorv' 
hormones or substrate supply in the early postprandial period when gluconeogenesis and 
hepatic glucose output are highest. After feeding, substrate supply and probably counter-
regulatory hormones are increased, but insulin also is stimulated markedly by feeding, 
therefore, insulin would act to minimize the conversion of amino acids and propionate to 
glucose (7). Thus, it would be interesting to study regulation of PEPCK gene expression by 
dietary factors such as feeding-fasting-refeeding and alterations of diet composition in 
ruminants. 
i 
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Metabolic Variations of Ketosis-susceptible Cows 
Our ketosis model. FRBD. consisted of overfeeding during the dry period to make 
cows obese and FRBD feeding in the early lactation period. These obese cows had 15.3% 
hepatic lipids and decreased hepatic glycogen content at d 7 postpartum and were susceptible 
to ketosis (26). They became hyperketonemic. and some later developed clinical ketosis by 
FRBD feeding during the experiment (26). 
The pattern of PEPCK mRNA in these cows differed somewhat from that of normal 
cows. Plasma insulin concentrations were significantly less in susceptible cows than in 
normal cows at d 7 postpartimi. but PEPCK mRNA abundance was similar in all groups 
(Figure 2). This result suggests that the susceptible cows may have failed to up-regulate 
PEPCK mRNA expression normally in the inunediate postpartal period. Later, during 
glucagon infusions, plasma insulin concentrations did not increase in STG cows, but PEPCK 
mRNA abundance did not increase as expected by stimulation of glucagon on PEPCK 
transcription. PEPCK gene expression in susceptible cows may be complicated by fatty 
liver. FRBD feeding, and glucagon infusions, and it is very difficult to define factors that 
have affected PEPCK mRNA abundance in these cows. However, it is clear that mRNA 
abundance in SC cows was greater overall than that in NC cows. 
Plasma glucose concentrations were significantly less in susceptible cows than in 
normal cows before glucagon infusions, but the net increase in average concentration of 
plasma glucose was greater in glucagon-treated cows than in NTG cows during glucagon 
infusions (17.3 vs. 10.1 mg/dl. Table 1). Also, plasma concentrations were affected 
significantly by FRBD feeding. Average concentration of plasma glucose during the first 
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week of FRBD feeding decreased compared with that one week before FRBD feeding in 
susceptible cows. In contrast average concentration of plasma glucose in one week after 
FRBD was greater than during the last week before FRBD ended. The responses in plasma 
glucose of susceptible cows to glucagon infusions and to FRBD feeding are consistent with 
the observations that substrate supply greatly regulates gluconeogenesis in ruminants (31) 
and that PEPCK mRNA expression and enzyme activity (5) did not decrease in cows with 
fatty liver and hyperketonemia. 
CONCLUSIONS 
The sizes of mRNA transcriptions for PEPCK. PC. and FBPase of dairy cows 
corresponded to those of rats, except that there was an additional minor transcript of about 
2.1 kb for FBPase in dairy cows. Concentrations of PEPCK mRNA decreased during shon-
term and wk 1 of long-term infiisions of glucagon, when plasma insulin concentrations were 
increased by glucagon infusions. Ketosis-susceptible cows in which plasma insulin was 
decreased and fatty liver was present may fail to up-regulate PEPCK gene expression. 
PEPCK mRNA concentrations were overall greater in cows with hyperketonemia and fatty 
liver than in normal cows. Abundance of PC mRNA was increased and FBPase abundance 
was not affected by 3.5-h glucagon infusions. Multiple liver biopsies during short-term 
glucagon infusions confirmed that glucagon stimulated initial net glycogenolysis. We 
conclude that PEPCK gene expression in normal cows is dovm-regulated potently by insulin 
to balance increased glycogenolysis and gluconeogenesis during glucagon infusions. We 
also suggest that PEPCK gene expression in cows with hyperketonemia and fatty liver may 
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be different from that of normal cows, but probably is not involved in the pathogenesis of 
bovine ketosis. 
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GENERAL SUMMARY 
The data presented in this dissertation are from the first known long-term 
administration of glucagon into lactating dairy cows, which also is one of the longest 
intravenous administrations of exogenous glucagon in mammalian species. Short-term 
infusions of glucagon also were conducted for comparisons with the effects of long-term 
infusions of glucagon. Whole body metabolic effects as well as changes in intracellular 
mRNA abundance of some gluconeogenic enzymes were determined to accomplish a general 
objective of providing better understanding of the regulation of carbohydrate metabolism in 
ruminants. Metabolic regulation of gluconeogenesis is emphasized in these smdies because 
ruminants depend on continuous gluconeogenesis to supply glucose. 
It was found that glucagon infusions at pharmacological doses stimulated an initial 
net glycogenolysis in the liver. The initial glycogenolysis was demonstrated clearly in the 
study of long-term infusions of glucagon by changes of liver glycogen, which decreased by d 
2 during infusions, but was restored completely by d 7 of infusions, and then continued to 
increase markedly, even through 3 d postinflision. These changes of liver glycogen reflect 
the regulation of liver glycogen metabolism by changes in hormonal and metabolic 
environments caused by long-term infusions of glucagon. Glucagon at high concentrations 
potently increased initial net glycogenolysis, but fiirther net breakdown of glycogen probably 
was blocked by increased endogenous insulin. Then, net glycogen synthesis was increased, 
probably by increased substrate availability caused by increased gluconeogenesis during 
126 
glucagon infusions. In addition, multiple biopsies during short-term infusions of glucagon 
confirmed that glucagon stimulated a net hepatic glycogenolysis during the first few hours. 
Although gluconeogenic rates and hepatic glucose output were not determined 
directly in our studies, increased gluconeogenesis caused by glucagon in normal cows was 
suggested indirectly by the three reasons. First, because daily lactose yield was not changed 
and daily milk yield was decreased slightly by glucagon infiisions, glucose utilization for 
milk production may have decreased very slightly. However, glucose utilization in muscle 
and adipose tissue could have been increased by increased concentrations of plasma insulin 
during wk 1 of glucagon infiisions and by constantly increased concentrations of plasma 
glucose. Therefore, total glucose utilization by peripheral tissues could have increased, 
especially in wk I of glucagon infusion. Second, glucose that was absorbed fi*om the 
gastrointestinal tract and absorbed gluconeogenic substrates could not have been increased b>' 
glucagon infiisions because feed intakes did not increase as occurred in normal control cows. 
Third, liver glycogen had been restored completely by d 7 of glucagon infusions and 
continued to increase markedly thereafter. Based upon these reasons, hepatic glucose output 
must have increased to provide additional glucose for possible increases in glucose utilization 
and to maintain increases in plasma glucose concentrations. Thus, the increased hepatic 
glucose output must have been firom an initial net glycogenolysis and later from increased 
gluconeogenesis. Milk protein yield significantly decreased during infusions, which implied 
decreased availability of substrates for milk protein synthesis in the marrunary tissue and also 
suggested that a shift of amino acids from protein synthesis to hepatic gluconeogenesis 
occurred. 
JU 
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While glucagon elevated carbohydrate status, glucagon infusions into normal cows 
decreased mRNA concentrations for the key rate-determining gluconeogenic en2:yme, 
PEPCK. These decreases were especially apparent in the short-term study where PEPCK 
mRNA decreased 41% after 3.5 h of glucagon infusions, whereas PEPCK mRNA in control 
cows increased 31% at the same time. The decreases in PEPCK mRNA is explained by the 
stimulation of endogenous insulin secretion during infusions of exogenous glucagon. Long-
term glucagon infusions decreased PEPCK mRNA in wk 1 of infusions, while plasma insulin 
increased. PEPCK mRNA concentrations were inversely associated with plasma insulin 
concentrations. We conclude that PEPCK mRNA expressions was down-regulated by 
endogenous insulin during glucagon infusions. 
We also found that short-term infusions of glucagon increased the abundsmce of PC 
mRNA. which is consistent with the findings by others that glucagon increased activity of PC 
and increased pyruvate carboxylation, thereby increasing the flux of OAA through PEPCK 
for gluconeogenesis. Others have shown that insulin potently inhibited gluconeogenesis. 
Our data suggest that decreases in PEPCK mRNA may reflect sensitive hormonal regulation 
of the PEPCK gene to offset increased net glycogenolysis and gluconeogenesis during 
glucagon infusions. We also showed that short-term glucagon infusions did not influence 
FBPase mRNA abundance and that the sizes of mRNA the major transcripts for PEPCK, PC. 
and FBPase of dairy cows corresponded to those of rats, except that there was an additional 
minor transcript for FBPase in dairy cows. 
Metabolic characteristics of ketosis-susceptible cows differed greatly from those of 
normal cows. We used the FRED protocol to induce ketosis. Cows were made obese by 
i1 
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overfeeding during the dry period, and they had fatty liver, decreased hepatic glycogen, and 
decreased plasma glucose during the immediate postpartal period. These cows were 
susceptible to ketosis, and some later developed a clinic ketosis caused by FRBD. Although 
plasma insulin concentrations in ketosis-susceptible cows at d 7 postpartimi were 
significantly less than those of normal cows. PEPCK mRNA concentrations were similar 
between groups, which may suggest that ketosis-susceptible cows can not up-regulate 
PEPCK gene expression. Also, long-term glucagon infusions did not affect concentrations of 
PEPCK mRNA and plasma insulin in susceptible cows. However. PEPCK mRNA 
concentrations were greater overall in cows with hyperketonemia and fatty liver than in 
normal cows. Also, plasma glucose concentrations in the ketosis-susceptible cows were 
changed significantly both by glucagon infusions and by FRBD feeding. Therefore, the data 
suggest that expression of the PEPCK gene probably is not involved in the pathogenesis of 
bovine ketosis. 
With respect to lipid metabolism, concentrations of plasma NEFA did not change in 
the long-term glucagon infusions and decreased in the short-term infusions of glucagon. It 
can not be concluded fi'om these results whether glucagon is lipolytic in ruminants because 
insulin was involved and because it is not known whether NEFA reesterification and 
oxidation were affected by glucagon infusions. Also, the effect of glucagon infusions on 
export of hepatic lipids and TAG in normal early lactation cows was not conclusive, and 
warrants ftuther study in susceptible cows. 
Further studies are warranted to ftuther refine understanding of the effects of 
glucagon infusions on glucose metabolism, as well as, on hormonal and dietary regulation of 
129 
gluconeogenic enzymes in dairy cows. By taking advantage of multiple blood samples and 
liver biopsies, regulation of carbohydrate metabolism by exogenous glucagon was studied in 
lactating cows in the current smdy. Other infusion techniques can be used to study more 
specific effects of glucagon or insulin. For example, a somatostatin clamp could be used to 
eliminate effects of endogenous glucagon and insulin, so that plasma concentrations of 
glucagon or insulin can be controlled more specifically. Also, a hyperinsulinemic 
euglycemic clamp could be used to smdy specific effects of insulin in vivo. Under well-
controlled conditions, in vivo regulation of gene expression of gluconeogenic enzymes can 
be determined more specifically for glucagon, insulin, and even glucose. Also, isotopic 
kinetic techniques sometimes are used to quantitatively study hormonal effects on metabolic 
regulation. The combination of genetic and isotopic techniques can provide new approaches 
for metabolic swdies in both nonruminants and ruminants. 
Another aspect that warrants further study is dietary regulation of gene expression. 
Gluconeogenesis occurs continuously in ruminant liver, and substrate supply is a major 
regulator of gluconeogenesis, but the mechanisms for this regulation by substrate supply are 
not understood. Our idea of dovm-regulation of PEPCK mRNA by insulin to offset increased 
glycogenolysis and gluconeogenesis caused by glucagon agrees well with Bassett's 
discussion (Bassett, J. M. 1978. Proc. Nutr. Soc. 37:273-280) that insulin increased and 
inhibited gluconeogenesis to balance the high gluconeogenesis in the early postparandial 
period. Thus, it would be informative to study regulation of PEPCK gene expression by 
dietary factors such as feeding-fasting-refeeding and alterations of diet composition in 
ruminants. 
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APPEENDIX A. SEQUENCE VERIFICATION OF PEPCK cDNA CLONES 
Two subclones for rat PEPCK cDNA. PCK.Lll and PCK.LI5 were derived from a 
full-length PEPCK mRNA clone, PCKIO (provided by Dr. R. W. Hanson. Case Western 
University, Cleveland. OH), and they were used as templates for making riboprobe and single 
strand DNA (ssDNA), respectively. Sequencing of PCK.Ll I and PCK.Ll 5 was performed 
to determine the precise size, orientation of inserts, and the vector used. By automatic 
sequencing at the Iowa State University DNA Sequencing Facility. PCK.L 11 was sequenced 
by using the reverse universal primer and PCK.L 15 was sequenced by using the forward 
universal primer. It was also determined that the sequences from the opposite ends in the two 
subclones were identical. PCK.L 11 could not be sequenced by universal primer and 
PCK.L 15 could not be sequenced by reverse primer because there were poly G sequences at 
one end of both subclones. Therefore, by using a manual DNA sequencing kit (USB 
Sequencing Version 2.0. United State Biochemical Corporation. Cleveland, OH). PCK.L 11 
was sequenced by universal primer. By comparing with PEPCK sequences in DNA 
databases from GCG (Genetics Computation Group), it was finally shown that PCK.L 11 was 
1405 bp long and ranged from the middle of exon 1 to the middle of exon 8 of the PEPCK 
gene. The length of PCK.Ll 1 was confirmed by digesting the cDNA with Pst I. Also, it was 
knovm that the inserts were cloned in pBluescript KS+. 
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APPENDIX B. QUANTITATION OF mRNA BY SOLUTION HYBRIDIZATION 
I. Procedures 
Supplies and Equipment: 
1. Water bath set at 72° C 
2. Water bath set at 37° C 
3. Microcentrifuge (at room temperature or 4° C) 
4. Beckman J-21 C Centrifuge with microfuge tube adapters 
5. Sterile 1.5 ml microcentrifuge tubes 
6. Various-sized pipettes with sterilized tips 
7. -20° C fireezer (for storage of cDNA) 
8. -70° C freezer (for storage of mRNA and cDNA) 
9. GF/C filters 
10. Scintillation counter (with capability of counting ["S]) 
11. Vortex unit 
Solutions and Reagents: 
1. ["S]-labeled cRNA probe 
2. mRNA samples 
3. PEPCK ssDNA 
4. Ice-cold 75% Ethanol 
5. Ice-cold 95% Ethanol 
6. Ice-cold Absolute Ethanol 
7.TE8 
8. RNase-free water (in kit or DEPC-water) 
9. 3M Sodium Acetate, pH 5.2 
10. 5M Sodium Chloride 
11.0.5M EDTA 
12. 2MTris, pH 7.5 
13. Formamide 
14. 20% SDS 
15. 0.1 M Dithiothreitol 
16. Melting Bath Oil 
17. RNase Buffer 
18. RNase salts 
19. 6M TCA (stored at 4° C) 
20. 5% TCA + 20 mM sodium pyrophosphate 
21. Non-toxic Scintillation Cocktail 
Methodology: 
1. Pellet the cRNA at 4° C at 12, 000 x g in a microcentrifuge for 15 minutes. 
2. Remove ethanol and add 0.5 ml ice-cold 75% ethanol. Vortex briefly. 
3. Centrifuge as in Step 1 for 10 minutes. 
4. Air-dry pellets. Dissolve cRNA in 100 ^1 of DEPC-water. 
5. Count cpm of 1 ^1 of cRNA probe. Calculate the amount of cRNA probe used for a 
total 2, 000,000 counts in the one ml of hybridization mixture, and use 20 fil of the 
mixture that should have 40,000 cpm for each tube. 
6. Dissolve ssDNA in TE 8 and quantitate ssDNA spectrophotometrically at 260 nm. 
Then dilute ssDNA into a concentration of 100 pg/|al. Use various amounts of 
ssDNA to make standards. For example, use 0, 100. 300, 500. 700. 900. and 1200 pg 
of ssDNA. Add DEPC-water to each tube to make a total of 20 ^1 of standard or 
samples. Measure all standards and samples in duplicate. 
7. Prepare your samples of total RNA after RNA isolation. Usually. 5 ng of total RNA 
was used for each sample. 
8. Prepare 1 ml of hybridization mixture: mix well. 
9. Dot 2 GF/C filters with 20 |al of the hybridization mixture. Air-dry filters and put in 
scintillation vials for determining cpm. 
10. Add 20 (il hybridization mixture to each tube of ssDNA or mRNA sample. Mix well. 
13. Overlay each sample with 2 drops of melting bath oil. Centrifuge briefly. 
14. Incubate overnight in a 72° C water bath. 
15. Cool samples to room temperature for 15 minutes. 
16. Add 1 ml RNase Buffer to each tube. Vortex briefly. Incubate for 45 minutes at 
17. Add 0.1 ml 6 M (100%) TCA. Vortex Briefly. Incubate on ice for 1 hour. 
18. Filter samples under vacuum through 5% TCA + 20 mM sodium pyrophosphate 
(NaPPi)-wetted GF/C filters. Then, rinse tubes with 1 ml of 5% TCA + 20 mM 
NaPPi and filter. Finally, rinse tubes with 1 ml ice-cold 95% ethanol and filter. Air-
dry filters. 
19. Count all filters for 2 minutes with 8 ml of scintillation cocktail. 
Buffer Preparations: 
Concentrated Hybridization mixture (prepare just before use) 
37 °C. 
5M NaCl 
0.5M EDTA 
2M Tris, pH 7.5 
240 ^1 
16 ^l 
20 ^1 
500 |il 
10 nl 
200 ^1 
Formamide 
20% SDS 
O.IMDTT 
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cRNA probe 
DEPC-water 
Ribonuclease Buffer (store at 4° C) 
lOx RNase salts 
Herring sperm DNA (2.0|ag/ml) 
DEPC-water 
Ribonuclease A (lO^g/ml) 
Ribonuclease T1 (5000,000 U/ml) 50 ^il 
100 ml 
RNase Salts (autoclave and store at room temperature) 
5 M NaCl 60 ml 
2 M Tris, pH 7.5 5 ml 
0.5 M EDTA 10 ml 
DEPC-water 25 ml 
100 ml 
II. Validation 
The principles of solution hybridization for quantifying PEPCK mRNA are described 
in Paper Two. Three criteria verified the accuracy of the method. 1) The assay was 
repeatable with very small intra-assay variation. The coefficient of variation (C.V.) of one 
sample measured five times within an assay was 2.8%. The C.V. for another sample 
measured five times between five assays is 9.8%. All samples in our assays were measured 
in duplicate, and the average C.V. for duplicate samples in an assay is 4.4%. 2) The assay is 
linear. The average square of the regression coefficient (r^) for standard curves in a total of 
24 assays that we did is 0.997. 3) In our assays, the cpm for all samples were corrected by 
vol. from #5 
to make 1 ml 
1 ml 
10 ml 
5 ml 
85 ml 
400 nl 
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background cpm. which were obtained by adding water rather than samples or standards to 
the tubes. The average background cpm in our assays were 387 ± 198, which is about 7.6°/b 
of the average cpm of the samples. It was found that the background levels are related to a) 
the amounts of radioactivity of riboprobes added to each tube, and b) the specific activity of 
["S]-UTP used for making riboprobes. Lower background counts were obtained by using 
["^Sj-UTP with specific activity > 1.000 than ["S]-UTP with specific activity > 400. 
It also should be pointed out that this method is not without disadvantages. Three 
points should be emphasized. First, the inter-assay C.V. tended to be great; so it is necessar> 
to carefully control the assay conditions, especially the amounts of radioactivity of 
riboprobes added to each tube. Second, a major issue when working with RNA is to prevent 
degradation. The sample should be analyzed as soon as possible, and mRNA samples were 
stored in 95% ethanol at -80 °C to prevent degradation. Third, in our assays, a low-degree of 
nonspecific binding may have existed in the samples. In the RNase protection assay, which 
is similar to solution hybridization, this problem is prevented by capturing specific 
hybridization after electrophoresis of the hybridized samples in solution. 
APPENDIX C. PEPCK mRNA EXPRESSION IN HEPG2 CELLS AND RATS 
Materials and Methods 
The objective was to study acute regulation of PEPCK mRNA in both cell lines and 
in diabetic rats for working out techniques and for demonstration of PEPCK mRNA 
regulation by cAMP, insulin, diabetes, fasting and glucose. In the HepG2 cell experiment, 
hepatoma cells, HepG2, were thawed from liquid N storage and cultured at 37 °C in 
Dulbeceo's modified eagle medium (DMEM) to confluence. The cells were then 
subcultured in Coming polystyrene dishes (100 x 20 mm) to about 90% confluence. Later, 
the cells were cultured in serum-free DMEM medium for about 24 h more. Finally. HepG2 
cells were treated with either 8-(4-chlorophorylthio)-cAMP [8-(4-CPT)-cAMP] or insulin for 
1 h. or at first with cAMP for 0.5 h, then with insulin for another 0.5 h. Total RNA was 
isolated, and PEPCK mRNA was analyzed by Northern blotting. 
All rats for the study with diabetic rats were from a classroom demonstration of the 
glucose tolerance test. Three days before treatment, all Sprague-Dawley rats were fasted for 
24 h. The next day, half of the rats were injected intraperitoneally with streptozotocin (50 
mg/kg BW). The streptozotocin was dissolved in cold 0.05 M citrate buffer, pH 4.5 (the half-
life of streptozotocin in this solution is about 2 min). Then, all rats were fasted for 16 h just 
before two normal and two diabetic rats were administrated a bolus of glucose (3 gm/kg BW) 
orally as a 20% solution by using a gastric mbe. These rats were decapitated 2 h later. 
Another two normal and two diabetic rats which served as zero time controls were 
decapitated without receiving glucose. Blood samples were collected and serum glucose 
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concentrations were measured by the glucose oxidase method. Total RNA was isolated from 
liver samples, and PEPCK mRNA was measured by both Northern blotting and solution 
hybridization. 
Results and Discussion 
PEPCK mRNA expressed in HepG2 cells was increased acutely by addition of 8-(4-
CPT)-cAMP and decreased greatly by insulin (Figure 2). It seemed that within the treatment 
time, insulin did not overcome cAMP to inhibit PEPCK mRNA expression (Figure 2. Lane 
5). Also, only one major transcript of PEPCK mRNA was detected from the bovine liver, 
and its size, 2.8 kb, was the same as that of other species. 
Figure 1. Northern blotting of PEPCK mRNA regulated by cAMP and insulin in HepG2 
cells. HepG2 cells were either untreated (Lane 1) or incubated with 0.1 mM 8-(4-
chlorophorylthio)-cAMP for I h (Lanes 2 and 3). 5 nM insulin for 1 h (Lane 4). or 
first 0.1 mM 8-(4-chlorophorylthio)-cAMP for 30 min, then 5 nM insulin for 30 
min (Lane 5). Bovine samples (Lane 6, 7, 8) in which 20 pg of total RNA, twice 
the amount of rat samples, were loaded in each lane. 
PEPCK mRNA in fasting normal rats was 8-fold greater than in fasting normal rats 2 
h after glucose injections, and was about the same as in fasting diabetic rats (Figure 3). 
Serum glucose in diabetic rats 2 h after glucose injections was 6-fold greater than in fasting 
diabetic rats, and PEPCK mRNA decreased by 62% in fasting diabetic rats 2 h after glucose 
injections. The result of PEPCK mRNA determined by solution hybridization was generally 
consistent with that determined by Northern blotting, but differences of PEPCK mRNA 
between treatments seemed to be greater when determined by Northern blotting (Figure 4). 
PEPCK mRNA in fasting normal rats 2 h after glucose injections was undetected and was 
greatly less in fasting diabetic rats 2 h after glucose injections than in non-injected fasting 
diabetic rats (Figure 4). 
1 2 3 4 5 6 7 8 
Figure 2. Northern blotting of PEPCK mRNA in fasted normal rats at zero time (Lanes 1 and 
2), fasted normal rats 2 h after oral injection of a solution of 20% glucose (Lanes 3 
and 4), fasted diabetic rats at zero time (Lanes 5 and 6), and fasted diabetic rats 2 h 
after oral injection of a solution of 20% glucose (Lanes 7 and 8). 
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fasted glucose 
Notmai 
lasted glucose 
Diabetic 
Figure 3. Changes in concentrations of liver PEPCK mRNA determined by solution 
hybridization (| ) and serum glucose ( B ) in fasted normal and fasted diabetic 
rats in response to glucose injection. A 20% glucose solution was given orally to 
rats as described in "Materials and Methods", and values were obteiined from fasted 
rats at zero time and 2 h after glucose injections. 
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Two reasons could explain the difference between Northern blotting and solution 
hybridization. First, this experiment was initiated in a classroom setting, and any delay in 
processing liver samples would cause degradation of PEPCK mRNA, which was shown as 
"tails" in Northern blots. Second, solution hybridization is a more sensitive method to 
measure quantities of mRNA than Northern blotting; therefore, it could have measured even 
partly degraded fragments of mRNA as shown in the current results. Interestingly, glucose 
feeding in diabetic rats caused a decrease in PEPCK mRNA, which may suggest that glucose 
at high concentrations inhibits PEPCK gene expression, assuming there were no increases of 
insulin in those rats. In summary, results from the preliminary studies demonstrated clearly 
that expression of PEPCK mRNA were acutely regulated by cAMP. insulin, fasting, diabetes, 
and glucose either directly or indirectly. 
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